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Abstract 
 Improving the solubility and changing the dissolution rate of the poorly soluble active 
pharmaceutical ingredients (API’s) AMG 517, glipizide, and naproxen through the preparation of 
eutectic mixtures was investigated.  Mixtures of the API’s with other small molecules were 
prepared to construct a phase diagram used to identify the eutectic mixture compositions.  The 
search for a eutectic mixture in a co-crystal phase diagram was investigated by mixing AMG 517 
with known co-crystal formers sorbic acid and trans-cinnamic acid.    Glipizide was mixed with a 
series of amides to investigate the presence of eutectic mixtures, but the thermal instability of the 
API was such that chemical degradation overwhelmed any other thermal transitions.  A phase 
diagram of naproxen and vanillin was prepared and the composition of the eutectic mixture 
identified.  The eutectic mixture at 0.11 MF naproxen vanillin (11% naproxen/ 89% vanillin) was 
found to have a melting point of 75 ºC.  The melt is reversible and thermally stable, as tested by 
multiple melts and coolings.  Further studies are planned to evaluate whether the eutectic mixture 
may be advantageous to develop.  However, expectations are modest due to the small amount of 
naproxen present in the eutectic mixture. 
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Chapter 1. Introduction 
Frequently Encountered Problems in Drug Development   
In the early stages of drug development, one frequently encounters novel molecules, which 
exhibit poor physicochemical properties.  For example, more than one third of the drugs listed in 
the U.S. Pharmacoeia fall into the poorly water-soluble or water-insoluble categories [1].  Prior to 
the 1980’s, such situations were rarely encountered as new chemical entities (NCE’s) often 
exhibited an aqueous solubility ≥ 10 μg/mL [2].  The emergence of large numbers of poorly soluble 
drug candidates has led to the necessity of developing strategies to overcome the limitations in 
drug product development associated with poor solubility.  One of approach is the preparation of 
eutectic mixtures of the drug with candidate utilizing various polymers or small molecules [3].  
Eutectic mixtures (from the Greek word meaning eutēktos [4] meaning “easily melted”) are 
composed of a specific ratio of drug another substance, which melt at a lower temperature than 
either of the original components [4-8]. 
Eutectic mixtures have not been a widely utilized technology in drug development, chiefly 
due to of the difficulty in forming a eutectic mixture, the inability to predict if a eutectic exists, 
and the time and resources necessary to characterize the these mixtures [3].  A eutectic system is 
a mixture of substances that have a single composition that solidifies at a lower temperature than 
any component that was used to form the system [9].  A particular composition displaying such 
characteristics is known as the eutectic composition and the temperature at which it solidifies is 
known as the eutectic temperature [4]. Eutectic mixtures compromise a subcategory of solid 
dispersions that form the basis of a formulation strategy wherein one seeks to improve the physical 
properties of the API to allow for an enhanced dissolution rate and apparent solubility [2, 10].  Not 
every drug and compound combination are capable of forming a eutectic mixture, with current 
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research being focused on predicting the presence of eutectic mixtures in silico [3].  At the time of 
this writing, the criteria for forming a eutectic mixture is largely unknown, with the desired results 
chiefly being obtained by serendipity and/or extensive trial and error experimentation. 
History of Eutectics 
Over the last 60 years, solid dispersions have been utilized to increase the solubility of a 
drug in a multiple of ways.  An advantage of a solid dispersion is to increase the surface area of 
the API and maximize the exposure of the drug particle to the surrounding media [11-13].  The 
state of the API in the solid dispersion may be crystalline or amorphous, since the dispersion 
mechanism may also prevent crystallization [11-14].  As a result, the intrinsic dissolution rate of a 
poorly soluble drug would be enhanced [11-15].  However, there are only a small number of 
examples where these dispersions were eutectic mixtures [10].  Eutectic mixtures are generally 
formed by three methods [9, 10, 12].  The fusion method is performed by melting a physical 
mixture of two thermally stable compounds, with subsequent cooling resulting in solidification 
and eutectic mixture formation [16].  The solid is then pulverized to provide a powder.  The second 
method employs the use of solvents [9, 10, 12].  Stock solutions of two compounds of similar 
solubilities in a solvent are prepared.  Mixtures are prepared by pipetting different proportions of 
the two solutions into a vial.  The final method is a hybrid of the first two methods.  One of the 
compounds is melted and the other compound is dissolved into a solution, then pipetted directly 
onto the melted compound, or vice versa [9].  All of the resulting mixtures are cooled, which results 
in solidification, followed by pulverization to prepare a homogeneous powder.  Once the mixtures 
are prepared, a composition-temperature diagram (phase diagram) is utilized to compare the melts 
of the mixtures by composition [16].  Historically the phase diagram was obtained by plotting the 
melting temperatures of the mixtures along the y-axis that correspond to the mixture composition 
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along the x-axis [4-7, 11, 16].  Today, eutectic mixtures can be characterized utilizing Differential 
Scanning Calorimetry (DSC) [9]. 
The pharmaceutical industry has had little success with developing a eutectic solid 
dispersion of a pharmaceutical agent.  Since 1961, when Sekiguchi and Obi described one of the 
first eutectic solid dispersions of a poorly soluble drug, there has been little progress in determining 
a pattern to regularly repeat the phenomenon of forming a eutectic mixture with other poorly 
soluble drugs [16].  Sekiguchi and Obi reported a phase diagram for the sulfathiazole-urea eutectic 
mixture, which was prepared by the thaw-melt method [8, 9].  They hypothesized that the two 
molecules were able to interact in a manner that retarded the nucleation of the mixture from a 
liquid to a solid [8, 9].  However, the application of this theory to predict eutectics between poorly 
soluble drugs has not been successful [5, 6, 16].  Eutectic mixtures have continued not make an 
impact in the pharmaceutical industry.  
Up to the present time, eutectic mixtures have not been vigorously pursued in the 
pharmaceutical industry to improve physicochemical characteristics of poorly soluble active 
pharmaceutical ingredients (API.)  In other industries, such as metallurgy and industrial 
construction, one frequently encountered the use of eutectic mixtures as alloys [8]. For example, 
eutectic alloys for soldering may be composed of tin, lead, silver, and gold.  Silicon chips are 
bonded to gold-plated substrates through a silicon-gold eutectic by the application of ultrasonic 
energy to the chip by eutectic bonding [17].  Metals are frequently more thermally stable and 
exhibit higher melting temperatures as compared to organic compounds.  Temperature plays a 
much different role in pharmaceutical compounds where lower melting points typically result in 
higher aqueous solubility.  An indication of the overall stability of a molecule can be measured by 
the heat of fusion, which may be viewed as the energy required to remove a molecule from its 
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neighboring molecules in the crystalline lattice, thus the transition from the solid state to the liquid 
state [11].  In general, when the heat of fusion is low, the observed melting  point will be low, thus 
the apparent solid state stability of the molecule could be considered more unstable relative to 
substance with a higher heat of fusion [11]. Organic compounds exhibiting low melting points may 
frequently be unstable with polymorphism and chemical degradation occurring with an increased 
frequency.  In metallurgy, thermal sensitivity is not a concern due to the use of high-melting metals 
involved in the formation of various alloys; however, this feature is not typical in pharmaceutical 
applications.  Therefore, despite the possible advantages of the low melting temperature of a 
eutectic mixture and the implications in solubility and the intrinsic dissolution rates, 
pharmaceutical scientists do not usually pursue the use eutectic mixtures in formulation 
development.  This may be due to a variety of reasons, but some of the main drivers may be time 
and resources.  One of the tools in searching for a eutectic mixture is by the preparation of a phase 
diagram, which is usually the result of a laborious manual process.  The phase diagram also 
requires an amount of experimental drug that usually exceeds what may be provided in the early 
stages of drug development [10].  Instead, the scientists may design a solid dispersion based on 
the reasons previously noted and/or the percentage of drug and compound was chosen to follow 
the necessary protocols that govern the in vivo/ in vitro dosings for solid dispersions [16].  
However, for some API’s with physicochemical properties difficult to overcome, the investigation 
of a eutectic mixture may be an option.  
Eutectic Mixtures and Dissolution   
Eutectic mixtures are advantageous as a means of changing the physicochemical properties 
of a drug because the specific ratio of API and compound may improve solubility and/or the 
intrinsic dissolution rate when compared to the other mixtures and drug alone.  This is a possibility 
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when the eutectic mixture forms a solid dispersion.  In 1971, Chiou and Riegelman [12] defined a 
solid dispersion as: “A dispersion of one or more active ingredients in an inert carrier or matrix at 
solid state prepared by melting, solvent evaporation or melt-solvent method.”  Solid dispersions 
may be amorphous or crystalline, and the crystal morphology of the crystals, if present, can be 
further defined [12, 22].  As a solid dispersion, the eutectic mixture releases very small particles 
that maximizes the surface area of the drugs to the aqueous surroundings [12, 16]. Also, the 
eutectic melt is lower than the melt of API and compound, and may have a higher solubility than 
the drug alone. The relation between the solubility and the dissolution rate is explained by the 
Noyes-Whitney equation, (Equation 1) [15, 19, 20]. 
dW
dt
= DA(Cs−Cb)
h
   Equation 1. 
 
The dissolution rate of the drug over time (dW/dt) (mg/cm2/mL) is described by the diffusion 
coefficient of the drug (D) (cm2/sec,) the surface area of the drug (A) (cm2,) the concentration of 
the drug in the bulk dissolution media (Cb) (mg/mL,) and the concentration of the drug in the 
dissolution layer around the surface of the drug (Cs) (mg/mL) [19, 20].  It is assumed that the drug 
is saturated in the dissolution layer around the mass of the solid and is the driving force of 
dissolution [19]. The thickness of the dissolution layer is defined by h (cm) in the equation.  The 
diffusion coefficient, D, depends on the molecular weight of the drug and the viscosity of the 
dissolution media.  The thickness of h is assumed to change during dissolution and be independent 
of particle size [15, 20].  Some intrinsic dissolution experiments enable the thickness of the 
saturated layer around the particle to be constant when a two-dimensional surface area is exposed 
with a controlled rotation rate.  Further the Noyes-Whitney equation is frequently normalized per 
surface area to obtain equation 2 [15-20]: 
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𝑀𝑀𝑀𝑀
𝐴𝐴𝑀𝑀𝐴𝐴
= 𝑀𝑀𝑑𝑑
𝑀𝑀𝐴𝐴
= 𝐷𝐷
ℎ𝐶𝐶
     Equation 2. 
In equation 2, the mass per area of the particle changes during time (Md/Adt) and is equal to the 
flux of particles during dissolution from the particle into the bulk media over time (dQ/dt).  This, 
in turn, is equal to the diffusion coefficient (D) divided by the thickness of the dissolution layer 
(h) multiplied by the concentration of the dissolved particle (C).  When examining equations 1 and 
2, the dissolution rate is directly proportional to the equilibrium solubility of the drug in the 
dissolution media.  This relationship is considered valid if the experimental conditions chosen to 
measure the solubility are the same as the parameters selected to measure the intrinsic dissolution 
rate.  This correlation was supported by comparing the initial dissolution rate to the solubility of 
numerous drugs of diverse structure [15].  The data was plotted on a log scale and demonstrated a 
linear relationship between solubility and the initial dissolution rate that extends over five orders 
of magnitude and no systemic deviation (Figure 1) [15]. 
The manipulation of solubility and surface area has given rise to various formulation 
strategies.  These strategies leverage the concepts described in the Noyes-Whitney equations where 
the dissolution rate is proportional to the surface area (equations 1 and 2.) Therefore, the 
formulation of a eutectic system as a solid dispersion may result in an increased dissolution rate 
due to the drug being dispersed as fine particles that may be amorphous or crystalline, thereby a 
greater drug release per unit area may occur [12, 13, 21].  It is also possible that when the eutectic 
mixture is released, the dissolved substances particles may become supersaturated when mixed 
with the local media, and then precipitates from solution as a very high surface area.  For many 
poorly soluble drugs, the dissolution rate best reflects the bioavailability of the compound [1, 11]. 
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Figure 1.  Data plot of the dependence of intrinsic dissolution rate on solubility as based on data 
of Hamlin, et al [15]. 
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For drugs where absorption rate is limited by dissolution rate, the reduction of the particle 
size may increases the rate of absorption and improve bioavailability [12, 23].  Eutectic mixtures 
have the potential to provide for improved oral absorption for some compounds by increasing their 
solubility and dissolution properties [3, 9, 16].  An example of a eutectic mixture where an 
increased the intrinsic dissolution was achieved for a poorly soluble drug is sulfathiazole and urea 
[13].  As mentioned earlier, Sekiguchi and Obi wrote one of the first scientific papers to propose 
eutectic mixtures as an approach to reduce the particle size and increase the dissolution rate [15, 
16, 22].  The sulfathiazole (mp 189 ° C) urea (mp 133 °C) eutectic mixture contained 52% 
sulfathiazole and 48% urea by weight and melted at 112 °C [16].  In a comparative experiment, 
eutectic mixture and the drug were orally administered and the resulting plasma levels compared 
[16.]  The results indicated that after ingestion of the eutectic mixture, the drug was absorbed at a 
faster rate than the corresponding dose of sulfathiazole alone, which was apparently due to the 
release of sulfathiazole as microcrystalline particles [13, 15, 16].  The diameter of the fine particles 
was determined to be less than one micron.  Therefore, the observed higher plasma levels of the 
drug was due to the increased surface area providing for an increased dissolution rate and 
ultimately increased bioavailability [24].  Although solubility of the eutectic mixture was not 
measured, numerous other solid dispersions have been characterized and found to exhibit a higher 
solubility as compared to the drug substance [12, 19, 25]. 
The relationship between melting point, solubility, and dissolution can be described in the 
general solubility equation (GSE) [23].  The GSE estimates the molar aqueous solubility of an 
organic non-electrolyte in the aqueous phase (Sw) as a function of its melting point (°C) and 
octanol-water partition coefficient (Kow) is described by equation 3 [26]. 
Log Sw = -0.01(MP-25) – log Kow + 0.5  Equation 3. 
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In recent publications, the melting points were related to the Log of solubilities [26].  By utilizing 
the GSE, the lower melting temperature of a compound may correlate with higher solubility [23, 
26].  When this concept is paired with the Noyes-Whitney equations (Equation 1 and 2), which 
uses factors such as solubility and surface area to describe the dissolution rate, it becomes logical 
that eutectic mixtures may enhance the intrinsic dissolution rate by increasing the solubility, as a 
result of the lower melting point, and due to an increase in the surface area of the drug.  To 
determine which factor contributes more to the intrinsic dissolution rate, the solubility of the 
eutectic mixture may be compared to the drug alone.  Also, the particle size of the drug in the solid 
dispersion can be measured by laser diffraction or microscopy.   
An example of a eutectic mixture in which the intrinsic dissolution rate and solubility was 
measured in vitro was by Goldberg’s study of the urea and acetaminophen (APAP) system.  The 
solubility of APAP in water was found to linearly increase as solid urea was added up to 0.23 (g/g) 
urea:APAP [6]. The dissolution rate of the eutectic mixture was also increased due to the solubility 
of APAP in the diffusion layer and thereby increased the dissolution of the drug.  It was also found 
that the coarser samples of the eutectic mixture also had a slower dissolution rate than the eutectic 
mixture with a smaller particles size [6].  Therefore, the faster intrinsic dissolution of the eutectic 
mixture was favored by the particle size and solubility. 
Utility of Eutectic Mixtures 
Eutectics may be formulated in a variety of dosage forms such as tablets, capsules, creams 
and suppositories [27].  Eutectics have been studied with respect to transdermal drug delivery and 
topical application.  These formulations take advantage of the lower melting point of the drug, 
which results in an enhanced transdermal permeation for the eutectic mixture of prilocaine and 
lidocaine [9, 27].  
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A marketed drug that exemplifies many of these desirable physicochemical characteristics 
is the Eutectic Mixture of Local Anesthetics (EMLA®).  EMLA®  has been found to be an effective 
means of decreasing pain for most children subsequent to surgery [31].   The eutectic mixture of 
the two drugs was discovered after the construction of the phase diagram [7].   The phase diagram 
was composed of prilocaine and lidocaine, which displays the melt of the various mixtures of 
prilocaine:lidocaine [7].  The eutectic mixture consists of a 1:1 stoichiometric ratio of 
prilocaine:lidocaine.  The eutectic point is 18 ˚C and renders the mixture a liquid at room 
temperature.  This greatly facilitated the preparation of the 1:1 eutectic mixture of the drugs into 
an oil-water cream because emulsification was directly accomplished without first dissolving the 
drug in the oil phase [2, 7].  For both drugs, the individual solubility is less than that of the eutectic 
mixture.  Therefore, the enhanced solubility between the two compounds was dependent on the 
ratio of the two drugs [7]. 
Phase Diagrams of Binary Mixtures  
 A binary phase diagram is a temperature-composition map which indicates the equilibrium 
phases present at a given temperature and composition [5, 12, 22, 28].  The equilibrium state can 
be found from the Gibbs free energy dependence on temperature and composition.  A phase 
diagram of a binary mixture is useful to visually depict the equilibrium state of the mixture and 
display the phases formed at a certain temperature and composition.  This knowledge can lead to 
the prediction of the phase the mixture may be when heated (solid or liquid) at a certain ratio of 
A:B and temperature.  A phase is represented by a single section of the temperature-composition 
diagram that contains similar physical chemical characteristics [28].  The number of phases in a 
system is described by the Gibbs Phase Rule where the system contains the number of degrees of 
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freedom (F) necessary to define the energy state of a system.  The Gibbs Phase Rule is described 
by equation 4 [11]. 
F  =  C – P + 2                  Equation 4. 
Where F is the number of degrees of freedom, C is the number of components, and P is the number 
of phases present at equilibrium [11].  The number of degrees of freedom is the least number of 
intensive variables, such as temperature, pressure, and concentration.  These variables must be 
fixed to describe the system completely [11, 18].  The components are the smallest number of 
independent variables in the system.  For example, it is possible to have a two phase system where 
two solids are immiscible in one phase and a single phase where both are miscible at a different 
temperature and composition.  From a knowledge of the phase diagram, it is possible to calculate 
the composition of each component in the two conjugate phases. 
Miscibility and Solubility in Phase Diagrams.  Phase separation may occur due to the 
degree of miscibility and solubility of each component in relation to the other in a heterogeneous 
mixture.  Solubility is a quantitative term that describes the concentration of solute in a saturated 
solution at a certain temperature [11].  The solvent and solute engage in a spontaneous interaction 
to form a homogeneous molecular dispersion [11].  In addition, the solubility of the substance also 
depends structural features such as the ratio of the polar to non-polar groups of the molecule [11]. 
Miscibility describes the ability of two molecules to form a uniform blend.  Blends of polar 
and semi-polar solvents are miscible in all proportions.  However, mixtures of polar and non-polar 
solvents are immiscible and will separate into discrete layers.  For example, salad dressing is an 
emulsion of oil (non-polar) and vinegar (polar) when mixed thoroughly.  However, when the liquid 
is at rest, the oil and vinegar equilibrates and separates into two layers of different densities.  In a 
phase diagram, the limited miscibility between two components can be detected by the emergence 
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of a second phase due to the addition of one component when the solubility is exceeded in the 
other.  From a knowledge of the phase diagram, it is possible to calculate the composition of each 
component in the two conjugate phases.   
 Free Energy of Mixing, ΔGmix.  The free energy of mixing, ΔGmix, determines if and to 
what extent two compounds mix to form a homogeneous phase [26.]   ΔGmix generally depends on 
the composition, temperature, and pressure of a system.    ΔGmix is the energy that is required or 
generated by mixing two components and is defined by equation 5 [15]. 
∆Gmix = ∆Hmix – T ∆Smix   Equation 5. 
The equation combines the effects of both enthalpy and entropy into a single parameter.  The terms 
in the equation are defined by: the enthalphy of mixing, ∆Hmix, (kJ/mol), the temperature, T 
(Kelvin), where the mixing occurs, and ∆Smix (kJ/mol/K) is the entropy of mixing [15].  If the free 
energy of mixing is negative, then mixing occurs.  If the free energy of mixing is zero, then the 
mixture separates into two phases.  When ∆Smix is positive, then the complete mixing of the two 
compounds is favored.  When ∆Smix is negative, then the system favors the two compounds 
remaining separate entities in a physical mixture [2].  By studying equation 4, it is apparent that 
∆Gmix is dependent on whether the enthalpy of mixing, ∆Hmix, is negative or positive.  The amount 
of mixing of the two compounds will be determined by the entropic and enthalpic factors for each 
compound and whether mixing is favored.15   For example, ∆Gmix may be occurring when two 
solids are mixed by mortar and pestle or by ball milling. 
The free energy of fusion, ΔG˚f, is described by equation 6, which signifies the difference in 
free energy between the products and the reactants during melting [11]. 
ΔG˚f = ΔH˚f - TΔS˚f   Equation 6. 
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In the above equation, ΔH˚f (kJ/mol) is enthalpy of fusion, and ΔS˚f (kJ/mol/K) is the entropy of 
fusion at temperature T (Kelvin.)   The ΔH˚f is only weakly dependent on temperature but ΔS˚f is 
strongly dependent on temperature due to the presence of T in the term.  For a pure crystal, the 
amount of entropy in the system, ΔS˚f, is practically zero.  Therefore, the change in free energy of 
the system before and after melting is equal to the heat of fusion released during melting of a 
crystal as described by equation 7 [5, 12, 30]. 
ΔG˚f = ΔH˚f   Equation 7. 
The Mixture Law.  If there is no energy associated with mixing between two compounds, 
then the difference between the enthalpy of fusion of the individual compounds before and after 
mixing should be the same.  Therefore, enthalpy of fusion of the mixture, (Δh˚f)mixture, can be 
calculated by the mixture law, as described by Equation 8 [4, 5, 15]. 
 (Δh˚f)mixture  = XAΔh˚fA + XBΔh˚fB  Equation 8. 
In this equation, the contribution of the heat of fusion for the mixture AB, (Δh˚f)mixture (kJ/mol,)  is 
the sum of the heat of fusion of A, Δh˚fA, multiplied by the mole fraction of A , X A (moles of A,) 
and the heat of fusion of B, Δh˚fB,  multiplied by the mole fraction of B (moles of B) in the mixture 
[15, 60].  The heats of fusion of the pure components determine Δh˚fA and Δh˚fB.   In a physical 
mixture, the free energy of the system before and after mixing is the same and there is no free 
energy generated due to mixing [15]. 
The enthalpy of mixing of a mixture, (Δh˚f)mixture , can be calculated by the mixture law 
(Equation 7) and compared to the experimental value as determined by thermal analysis [5, 15].  
If the mixture is a physical mixture, and no interaction occurs during melting, the calculated and 
experimentally measured enthalpy of fusion, ΔH˚f, will be virtually the same.  However if an 
interaction does occur during melting, as in the solubility of a poorly soluble drug is increased by 
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the melt of another compound, then the difference between the values will be negative or positive.  
The negative and positive values will further describe the melting process as spontaneous 
(negative) or not spontaneous (positive) [11].  
 Construction of Phase Diagrams. 
Differential scanning calorimetry (DSC) is a highly sensitive technique widely used to 
determine the melting temperature and other thermodynamic parameters of materials.  The DSC 
provides information about thermal changes that do not involve a change in sample mass [11].  
Thermocouples in the DSC measure the difference in heat flow between a “sample” and a 
“reference” as a function of changing temperature.    Information about the sample such as the 
enthalpy of fusion, purity, and melting point can all be determined [32].  Eutectic mixtures are 
combinations of two unique compounds, so the DSC trace will reflect the eutectic mixture as a 
unique phase of material.   
Today, a phase diagram can be constructed by interpreting the DSC traces of mixtures. 
Mixtures that contain two components will have respective endotherms that may be affected by 
the melting behavior of each component.  This will result in a melting point depression.  In a DSC 
trace, the composition of the mixture will dictate the temperature and shape of the endotherm.  The 
DSC traces of three types of melts are described in Figure 2 [9].  The actual construction of the 
phase diagram relies on the transfer of thermal information recorded from the DSC curves to the 
phase diagram (Figures 3a and b.)  When the DSC curves of the entire range of mixtures are 
overlaid, the pattern of the phase diagram can be seen.  For example, in Figure 3a, the DSC traces 
of the mixtures are overlaid to coincide with the melts of the phase diagram in Figure 3b.   
The phase diagram is constructed by matching the DSC curve with the two points plotted 
on the phase diagram that represent the solidus and liquidus curve.  As can be seen in curves 2, 3,  
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Figure 2.  Three theoretical differential scanning calorimetry (DSC) traces show the 
determination of an onset melt of a pure compound (top, Tm,).  Middle trace is a mixture with 
two compounds that melt at different temperatures.  The initial melt of the mixture (Ts) is the 
melt of the lower melting compound.  The temperature at which both compounds melt 
completely is the liquidus temperature (Tl .)  The bottom trace is the melting behavior of a 
eutectic mixture where both components have a unified melt (Te ) and the melting temperature is 
determined at the bottom of the endotherm [9] as described in Figure 2 [9].  The top trace is the 
sharp melt indicative of a pure component (Tm.)   The middle trace is the melting behavior of a 
mixture that has two components melting at different temperatures (Ts, Tl ).  The endotherm of 
the lower melt in the mixture, Ts , is measured at the onset of the melt of the melt of the mixture 
and the melt of the higher melting component, Tl, is measured from the broad endotherm at the 
highest temperature before it returns to baseline [9].  On the phase diagram, the solidus boundary 
is plotted by Ts and the liquidus boundary is plotted by Tl . The melt of the eutectic mixture, 
bottom trace, has a unified melt and the eutectic temperature, Te, is measured at the lowest point 
of the endotherm.  The eutectic melt is also plotted as a part of the solidus boundary of the phase 
diagram [25]. 
  
15 
 
 
 
 
 
 
 
 
Figures 3a and b.  The transfer of thermal information from a DSC curve (3a) to a phase 
diagram (3b) [32]. 
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and 5, the composition ratios between pure material and the eutectic point show sharp endothermic 
peaks at the initial melt of the lower melting compound in the mixture.   
The actual construction of the phase diagram relies on the transfer of thermal information 
recorded from the DSC curves to the phase diagram (Figure 3a and b.)  When the DSC curves of 
the entire range of mixtures are overlaid, the pattern of the phase diagram can be seen.  For 
example, in Figure 3a, the DSC traces of the mixtures are overlaid to coincide with the melts of 
the phase diagram in Figure 3b.  The phase diagram is constructed by matching the DSC curve 
with the two points plotted on the phase diagram that represent the solidus and liquidus curve.  As 
can be seen in curves 2, 3, and 5, the composition ratios between pure material and the eutectic 
point show sharp endothermic peaks at the initial melt of the lower melting compound in the 
mixture.  As the temperature increases, the endotherm broadens as the entire sample liquefies and 
eventually returns to the baseline.  A phase diagram is useful because the melt of an unknown 
binary mixture can be determined by using the x- and y-axis of the phase diagram [9]. 
 Types of Binary Phase Diagrams. 
 There are many types of binary phase diagrams, but the discussion will only include 
systems that were encountered over the course of the present research.  All phase diagrams imply 
the thermal stability of the mixtures where the temperatures of melting and resolidification are 
plotted.  If the mixtures are not thermally labile, then an overlay of DSC curves of the mixtures 
can demonstrate the effect of melting the two compounds.  However, in some cases, half of the 
phase diagram may be plotted if the mixtures that contain a majority of the higher melting 
temperature compound has minimal degradation. 
 1. Simple Eutectic Mixtures.  The phase diagram of a simple eutectic mixture, where 
there is no solubility between the compounds in the solid state, is illustrated below (Figure 4) [9, 
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22].  The melting temperatures of the mixtures and pure components is plotted against mixture 
composition (x-axis) and temperature of the melt (y-axis.).  The range of mixtures of A:B reflects 
the changing proportion from left (100% A/ 0%B) to right (0% B/ 100% A) of the mixtures and 
the pure components.  There are three phases in the phase diagram.  The liquid phase is one phase 
of melted A and B.  The mixed phase, liquid + solid A, occurs at temperatures below the liquidus 
curve where the solid A begins to solidify and B remains a liquid as the temperature decreases.  In 
the mirror image of this phase, liquid + solid B, liquid is present as solid B solidifies as the mixture 
is cooled.  The solidus is the minimum temperature at which both components will solidify and 
represents is the boundary between the mixed phase and the solid phase of the two compounds [9, 
22]. 
The thermal behavior of the eutectic mixture can be explained by the eutectic phase 
reaction where the liquid separates into two solids upon cooling below the eutectic temperature as 
described by equation 9 [22]. 
Liquid  A + B    Equation 9. 
If the eutectic mixture is heated to the liquid phase and then cooled, the liquid will solidify at the 
eutectic temperature and all three phases will be present.  The eutectic temperature is the 
temperature of the eutectic melt and plotted at the solidus line.   The eutectic temperature is also 
invariant.  When the eutectic mixture is cooled below the eutectic temperature, the two components 
will resolidify into the solid phase of A and B.  The eutectic phase reaction is also a reversible 
reaction (Equation 8) [18].  At the eutectic point, all three phases are present simultaneously and 
can be seen by microscopy. 
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Figure 4.  Phase diagram of a simple eutectic system [9, 22]. 
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2. Co-Crystal Phase Diagrams.  Pharmaceutical co-crystals are molecular complexes of 
API of one or more co-crystal former, which are solids at room temperature and formed mainly 
through hydrogen bonding [33, 35].  The co-crystal is considered a new form of the API (Active 
Pharmaceutical Ingredient) and may possess different physicochemical properties than the original 
API.  The construction of co-crystals phase diagrams are necessary to find the eutectic mixtures 
that may present different physicochemical properties than the original co-crystal.  Interest in the 
eutectic mixtures of co-crystals lie in the eutectic melting temperature below the original co-crystal 
[36].  
There are few examples of binary co-crystal phase diagrams for a poorly soluble API's that 
have been published [33, 35].   A 1:1 co-crystal phase diagram contains two eutectic mixtures and 
no solid solubility between the compound and co-crystal former (Figure 5) [33].  The 
characteristics of a 1:1 co-crystal phase diagram are:  1.) a eutectic point, E1, to the left of the co-
crystal melt, Tcoc, 2.) a second eutectic point, E2, to the right of Tcoc , and  3.) Tcoc melts at a higher 
temperature than either eutectic point E1 or E2 [15]. 
The characteristics of a 1:1 co-crystal phase diagram are a eutectic point, E1 (to the left of 
the co-crystal melt, Tcoc), a second eutectic point, E2, (to the right of Tcoc) and Tcoc, which melts at 
a higher temperature than either eutectic point, E1 or E2 [15].  For the purposes of illustration, 
compound A will be the poorly soluble API and B will be the co-crystal former.  The data points 
of the co-crystal phase diagram are plotted by the composition of the mixture (x-axis) and the 
melting temperature of the mixture (y-axis).  Some of the phases are similar to the eutectic phase 
diagram discussed above with a few exceptions.  For example, there are two solidus lines that are 
aligned with the eutectic melt of E1 and E2 that occur at slightly different temperatures.  Below this 
line, both compounds are solids, and above this boundary one of the compounds begins to  
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Figure 5.  A typical co-crystal phase diagram for a 1:1 co-crystal.  There two eutectic melts, E1 
and E2, which occur at a temperature below the co-crystal melting temperature (Tcoc) [33, 35]. 
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melt.  The mixed phases of co-crystal and component A or B are formed above the solidus line.    
These phases contain melted co-crystal and solid component A or B.  As the 1:1 stoichiometry of 
the co-crystal is approached in the mixtures, the liquidus curve is not always possible to obtain a 
full co-crystal phase diagram because of the thermal stability of the compounds and/or the 
difficulties in mixing the compounds homogeneously [33 – 35]. 
Introduction of AMG 517, Glipizide, and Naproxen. 
 The purpose of this work was to investigate eutectic mixtures in three small molecules:  
AMG 517, naproxen, and glipizide (Figure 6) [35, 37, 39].  All of these drugs suffer from poor 
solubility and a slow dissolution rate, both of which contribute to limiting bioavailability.  These 
drugs were chosen for the investigation of eutectic mixtures because of the potential to increase 
solubility and, perhaps, change the intrinsic dissolution rate.  AMG 517 is a potential vanilloid 1 
receptor antagonist (TRPV1) that was developed by Amgen, Inc. for the treatment of chronic pain.  
The API was chosen because of stability at high temperatures and the ability to form co-crystals 
in specific conditions [35].  AMG 517 was investigated by the fusion and solvent method to form 
co-crystal phase diagrams and discover the possible eutectic mixture(s). Although solubility was 
not the issue that removed AMG 517 from the clinic, the molecule is useful to study due to its low 
solubility and dissolution rate [35].  Naproxen is a small molecule often employed to treat mild 
chronic pain as a non-steroid anti-inflammatory drug (NSAIDS).  Naproxen is also thermally 
stable and has a lower melting point (153 ˚C), enabling it to melt at lower temperature with a 
complimentary compound [39].  The ability to make a eutectic mixture was investigated because 
naproxen is widely available, easily accessible, and exhibits low toxicity.  Finally, glipizide is a 
small molecule that is widely prescribed for Type II diabetes [40]. It was also chosen to investigate 
eutectic mixtures because of low solubility in aqueous media  
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Figure 6. AMG 517 (top) [35], glipizide (middle) [39], and naproxen (bottom) [37]. 
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and slow dissoluton rate.  However,glipizide is not thermally stable, so the preparation of eutectic 
mixtures by the fusion method would be closely monitored for evidence of degradation.   
During the experiements, if the drug displayed a depressed melt when heated with another 
compound or eutectic mixture was suspected to have been prepared, then the mixture was further 
evaluated in solubility experiments in DI water and PBS.  Ultimately, if the solubility of the poorly 
soluble compound was increased in either media, then intrinsic dissolution experiments would be 
designed.  If the intrinsic dissolution rate was found to be increased as well, then the 
pharmaceutical scientist would be able to use these parameters to select not only other forms of 
the drug, if possible, but to evaluate the possible bioavailability in vivo of the eutectic mixture as 
well. 
Conclusions. 
 Eutectic mixtures have been investigated for pharmaceutical purposes since the 1960’s and 
serve in various functionalities across industries.  Interest has amplified over recent in years in the 
pharmaceutical industry due to advances in thermal analysis. With increased knowledge, in the 
future there may be sufficient information available to promote eutectic mixtures as a major 
strategy to overcome API physical propertery limitations.   
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Chapter 2. Background 
Urea-Benzoic Acid:  A Model Eutectic System 
 Introduction.  A simple model eutectic binary system comprised of urea (U) and benzoic 
acid (BA) has previously been established (Figure 1) [1].  U and BA mixtures have no solid 
solubility at room temperature and one eutectic point [1 – 3].  The purpose of this work was to 
compare the preparation of the U:BA phase diagram using DSC analysis and ball-milling to the 
thaw-melt (or fusion) method as previously published [1, 5]. 
Some methods of preparing eutectic mixtures are well-established:  the fusion method, the 
solvent method, and the hybrid fusion-solvent method.  All of these methods rely on the ability to 
form a homogeneous mixture of two compounds.   Ball milling is another method that can be used 
to form homogeneous mixtures of two, or more, compounds.  In this work, ball milling was 
investigated as a method to prepare homogeneous mixtures of U:BA used in the preparation of the 
2-component phase diagram.  
The 2-component phase diagram of U:BA mixtures have been previously published by 
Rai, et al [1].  They used the fusion method to construct the phase diagram [1, 5, 6] with the 
experiments being performed by filling capillary tubes with physical mixtures of U and BA in 
different proportions, followed by repeated melting and freezing.  The temperatures at which the 
mixtures would thaw and melt were visually observed and recorded.  On heating the solidus 
temperature was noted when the mixture first began to melt.  The liquidus temperature was marked 
when the mixture completed melted.  During cooling, the liquidus temperature was recorded when 
the liquid first began to solidify and the solidus temperature was marked again when the mixture 
completed solidified.  This cycle was repeated as needed.  The eutectic mixture was identified as 
the mixture composition where the solidus and liquid curves met.  The U:BA system was chosen 
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because it was known and the difference in temperature between the eutectic and liquidus melts 
was large (> 50°C), which should aid detection, and the compounds were readily available making 
it a good system to use to develop the experimental techniques that would be used throughout this 
research project. 
Experimental. 
Materials.  Urea (U) was purchased by Fluka (lot1328820) and used as received.  BA was 
purchased by Spectrum (lot VC116) and used as received. 
Preparation of eutectic mixtures.  U and BA, 25 mg combined, were weighed into tared 
aluminum weigh boats and transferred into 1.5 mL Retsch ball jars.  A 5 mm stainless steel ball 
was added to each ball jar, and then placed into the Retsch ball mill (Retsch, Inc. Newton, PA.)  
The ball jars were agitated for 2 minutes at 30 Htz.  The mixtures were then removed from the ball 
jar and analyzed.  The mole fractions (MF) of BA were calculated by adding the total number of 
moles in the mixture, and then dividing the total by the number of moles of BA [6].  The mixture 
attains equilibrium at different phases in the phase diagram.  When the eutectic mixture solidifies, 
it forms a microstructure that can be detected by microscopy [6]. 
 Differential Scanning Calorimetry (DSC.)  Physical mixtures prepared for the phase 
diagram were analyzed by DSC on a TA Instruments Q100 calorimeter.  The melting temperature 
of the mixtures were determined by one DSC sample per mixture.  The weights of the DSC samples 
and the standard deviation between the DSC weights was recorded (1.17 ± 0.12 mg.)  The samples 
were equilibrated at 25 °C, and then ramped to 275 °C at 10°C/min in aluminum hermetically 
sealed DSC pans.  The enthalpies of fusion were determined by integrating the endotherm of the 
onset melt of the mixture. 
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Figure 1.  Chemical structures of U and BA [2, 3]. 
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Further analysis involving the 0.2 MF mixture, 0.6 MF mixture, 0.442 MF eutectic mixture, 
and 0.8 MF mixtures were analyzed in a heating/cooling cycling experiment.  Sample sizes of 3.25 
± 0.25 mg were weighed into a hermetically sealed DSC pan and equilibrated to 25 °C.  The sample 
was then heated to 125 °C at 5 °C/min and cooled to 25 °C.  Each sample was heated and cooled 
in three cycles, except for the 0.6 MF mixture which was heated and cooled to the same 
temperature range twice.  The data obtained for the 0.2, 0.6, and 0.8 MF mixtures are included in 
the Appendix. 
 X-Ray Powder Diffraction (XRPD).  The XRPD data were obtained for U, BA, and the 
0.442 MF U:BA mixture.  The data were obtained on a PANalytical X’Pert PRO X-ray diffraction 
system with RTMS detector.  Samples were scanned in continuous mode from 5-45 ⁰ (2θ) with 
step size of 0.0334 ⁰ at 45 kV and 40 mA with CuKα radiation (1.54 Å).  The incident beam path 
was equipped with a 0.02 rad soller slit, 15 mm mask, 4 ⁰ fixed anti-scatter slit and a programmable 
divergence slit.  The diffracted beam was equipped with a 0.02 rad soller slit, programmable anti-
scatter slit and a 0.02 mm nickel filter.  Samples were prepared on a low background sample holder 
and placed on a spinning stage with a rotation time of 2 s.   
Results and Discussion 
 Phase Diagram.  The DSC curves from the experiment (Figure 2) were overlaid to 
construct the U:BA phase diagram below (Figure 3).  In both figures, the melting temperature of 
U decreases with the addition of BA as it reaches the eutectic temperature at the eutectic point.  At 
this point, the system is invariant [6, 7].  When the eutectic mixture is heated above the eutectic 
temperature, the mixture melts into liquid.  The eutectic temperature becomes the solidus boundary 
[1, 6, 7].  The experimental eutectic point is located at 0.442 MF mixture, which is the same 
eutectic mixture composition as previously reported [1]. 
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Figure 2.  (Top) DSC curves of ball milled mixtures of U and BA.  Mixtures are arranged with 
BA at the top and then mixtures of increasing amounts of U being added to the system 
progressively move downward.  (Bottom) U:BA phase diagram.  The melting temperatures of BA 
and U are indicated with solid (BA) and dashed (U) lines across the phase diagram.  A solid black 
line follows the depressed endotherms from pure U (right) down to pure BA (left).   
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 As more BA is added to the system past the eutectic point, the melting point of the mixture 
increases until the melting temperature of pure benzoic acid is obtained.  The eutectic point is at 
0.442 MF (E).The experiment resulted in an observed melting temperature of the eutectic mixture 
at 83.6 °C versus 87.5 °C from literature [1].  The thaw-melt method that was followed in the 
literature heated and cooled the mixtures at a different rate as compared to the rate used in the 
present work.  The heating rate for the mixtures in the present DSC experiment (10 ˚C/min) was 
faster than the original published experiment and may play a factor in the discrepancy between the 
melting and cooling temperature of the mixtures when compared, although faster heating rates are 
often associated with a shift to higher temperatures.  The most important aspects from the 
comparison of the experimental and literature techniques for analysis are:  the shape of the phases 
in the diagrams are similar, the eutectic mixtures occur at similar temperatures and the same 
mixture composition, and the other U:BA mixtures displayed similar thermal behaviors as the 
published experiments [1]. 
 XRPD Analysis.  The detection of an unknown form of an Active Pharmaceutical 
Ingredient (API) can be determined by the presence of unknown melts when a mixture is heated 
and analyzed by DSC.  The confirmation of the new form can be aided by the observation of a 
unique XRPD pattern.  To determine whether or not a new form was discovered during the ball 
milling process to prepare the mixtures, the XRPD patterns of the original compounds and the 
0.442 MF eutectic mixture were compared.  The peaks of the original compounds (top and bottom 
traces) are also are present in the 0.442 MF U:BA eutectic mixture (middle trace).  These results 
confirms a physical mixture and not the presence of a new form (Figure 3).   
 DSC cycling experiments.  DSC heating/cooling cycling experiments were conducted to 
verify the reversible phase formation of various mixture compositions of U and BA.  This DSC  
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Figure 3.  Overlay of XRPD traces of U (top red trace), the 0.442 MF U:BA mixture (middle 
trace), and BA (BA, bottom blue trace.) 
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method would be similar to the thaw-melt method published previously [1].  The heating/cooling 
cycle will be useful to analyze the melting behavior of mixtures because the data provides a solidus 
and a liquidus temperature that can be plotted on a phase diagram.  The resulting melting 
endotherms will refer to the melt of the mixture and the exotherms correspond to the melt re-
solidifying into the original components.  If a mixture does not exhibit this reversible phase 
transition, then it cannot be classified as a eutectic. 
 The mixtures chosen for heating and cooling all displayed the ability to melt and reform to 
the original components.  The only difference between the other mixtures and the eutectic 
composition was that at the eutectic composition a lower melting temperature was observed.  The 
DSC trace of the 0.442 MF mixture, the eutectic composition identified from heating/cooling 
experiments, is shown in Figure 4.  The sample was heated and cooled in three consecutive cycles 
that ranged from room temperature (25 ˚C) to the melting temperature of benzoic acid.  The onset 
melting temperature of the mixture occurred at 77 ˚C (± 2 °C), slightly below the reported eutectic 
melting temperature and ~ 7 °C below the eutectic melting point from the first freeze-thaw cycle.  
The exotherms that correspond to re-solidification of the original compounds upon cooling were 
fairly consistent (44 ˚C ± 4 ˚C.)  All of the mixtures were thermally stable and did not show 
evidence of degradation.  The lack of degradation and the consistent onset melting temperature 
and resolidification of the mixtures are characteristic of the eutectic phase transition [1, 6, 7].  The 
heating and cooling cycling technique can therefore be used to test future mixtures for evidence of 
eutectic formation.   
 Thermochemistry.  The enthalpies of fusion of the pure components and eutectics are 
significant to determine the mechanism of solidification/crystallization as the eutectic mixture 
cools [1, 4, 7].  The specific mechanism of solidification of the eutectic mixture of U and BA is  
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Figure 4.  DSC overlay of three cycles the 0.442 MF eutectic mixture heated and cooled during 
the DSC cycling experiment.  The melting of urea and BA is a reversible reaction, which can be 
seen by the melt at 77°C - 80 °C and the accompanying recrystallization which occurs between 41 
°C - 48°C.    
  
84.30ЎC
79.70ЎC
105.9J/g
79.56ЎC
76.66ЎC
122.7J/g
48.06ЎC
44.44ЎC
41.32ЎC
-6
-4
-2
0
2
4
6
H
ea
t F
lo
w
 (W
/g
)
20 40 60 80 100 120 140
Temperature (ЎC)
Sample: 0.442 MF Urea Benzoic Acid BM Circuit 3
Size:  3.2490 mg
Comment: BM 2min30htz, HermSeal, 25C->125C; 125C->25C thrice
DSC
File: 0.442 MF Urea Benzoic Acid BM Circuit...
Operator: CMorgan
Run Date: 01-Nov-2012 17:56
Exo Up Universal V4.7A TA Instruments
35 
 
 
 
beyond the scope of this work, but the enthalpy of fusion, enthalpy of mixing, and melting point 
can be determined [1, 5, 7]. 
Conclusion 
The U:BA system is a useful system to determine a new method to prepare and analyze 
eutectic mixtures. The phase diagram of mixtures of U: BA was prepared and the eutectic mixture 
was identified.  The experimental results were very similar to the data previously published in 
literature.   
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Chapter 3. AMG 517 Binary Systems 
 Introduction.  The goal of this work was to utilize a novel underutilized strategy to 
enhance the solubility and may change the intrinsic dissolution rate of AMG 517.  This was in 
binary AMG 517 systems known to form small molecule co-crystals.  Few eutectic mixtures have 
been pursued vigorously in the pharmaceutical industry for a variety of reasons (Chapter 1).  
Eutectic mixtures, however,  might present one part of the solution to evaluate or develop  
compounds exhibiting dissolution limited bioavailability.   
AMG 517, a vanilloid 1 receptor antagonist (TRPV1) being developed for the treatment of 
chronic pain, is an anhydrous freebase small molecule that encountered challenges in development 
due to various physicochemical characteristics, such as poor solubility in water and buffers at 
physiological pH  (Figure 1) [1].  Salt formation was unsuccessful in overcoming the solubility 
limitation to in vivo exposure due to rapid disproportionation and precipitation of the insoluble 
freebase hydrate in aqueous media  The other existing forms of AMG 517 also have low solubility 
in aqueous media resulting in these forms being unsuitable for development [1, 2].  The drug is 
also thermally stable and melts at 226 - 230 ˚C, which presented AMG 517 as a candidate to form 
eutectic mixtures by the fusion method [3, 4].  Due to the  thermal stability of the API,  and the  
exhistence of several co-crystals, AMG 517 was utilized in this study in a search to find a eutectic 
mixture [3, 4, 7]. 
In this work, the two component phase diagrams for AMG 517 and another compound, for 
example the co-crystal former sorbic acid (SA), were prepared and evaluated.  The preparation of 
the mixtures necessary to construct the phase diagrams of AMG 517 and the small molecules was 
accomplished by ball milling or solvent evaporation [3, 4].  Phase diagrams were prepared for 
AMG 517 with the following small molecules: the SA, trans-cinnamic acid (CA), xylitol (XYL), 
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Figure 1.  Chemical structures of AMG 517, SA, CA, XYL, MAN [2, 12]. 
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and mannitol (MAN) (Figure 1) [8– 10].  The co-crystal phase diagrams of AMG 517 and SA and 
AMG 517 and CA were also investigated. Differential scanning calorimetry (DSC) is a common 
method to discover eutectic mixtures by comparing the melting points across a series of mixtures 
[3, 4, 7, 8 -11]. 
Experimental 
 Materials:  AMG 517, the AMG 517 SA co-crystal (AMG 517/SA), the AMG 517 CA 
co-crystal (AMG 517/CA), and AMG 517 hydrate (AMG 517·H2O) were synthesized by Amgen 
medicinal chemistry [1, 13].  SA, CA, MAN, tetrohydrofuran (THF), and XYL were purchased 
from Sigma Aldrich and used as received.  Methyl ethyl ketone (MEK), diethyl ether, acetone were 
all purchased from JT Baker.  Ethanol (EtOH) was purchased from Pharmco.  All compounds were 
stored on the bench top, except for AMG 517,  AMG 517/SA, AMG 517/CA,  and the AMG 
517·H2O which were stored in room temperature desiccators.   
 X-Ray Powder Diffraction (XRPD).  XRPD patterns were obtained on a PANalytical 
X’Pert PRO X-ray diffraction system (Almelo, the Netherlands).  Samples were scanned in 
continuous mode from 5-45 º (2θ) with step size of 0.0334 º on a spinning stage at 45 kV and 40 
mA with CuKα radiation (1.54 Å).  The incident beam path was equipped with a 0.02 rad soller 
slit, 15mm mask, 4 º fixed anti-scatter slit and a programmable divergence slit.  The diffracted 
beam was equipped with a 0.02 rad soller slit, programmable anti-scatter slit and a 0.02 mm nickel 
filter.  Samples were prepared on a low background sample holder and placed on a spinning stage 
with a rotation time of 2 sec.  Detection was accomplished with an RTMS detector (X’Celerator).  
Data analysis was conducted with PANalytical X’Pert Data Viewer software. 
 Thermal Analysis Methods.  DSC was performed on a TA Instruments Q100 calorimeter 
(New Castle, DE) at 10 ºC/min from 25 to 275-300 ºC.  The melts of each mixture in the phase 
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diagram was determined by one DSC sample as analyzed in hermetically sealed pans, except for 
the AMG 517 and SA mixtures (AMG 517:SA) and the AMG 517/SA mixtures, which were 
analyzed by open DSC pans.   
AMG 517:SA mixtures were weighed into DSC pans in triplicate (2.81 ± 0.27 mg) and 
analyzed in open and hermetically sealed DSC pans, but only data obtained by open DSC pans 
were ultimately used to compare the melts of the mixtures prepared for the phase diagram.  One 
of the melts of the mixtures analyzed in triplicate was chosen as representative of all three and 
overlaid in Figure 3.   
Some, such as the AMG 517:XYL mixtures, were also analyzed by thermal gravimetric 
analysis (TGA).  This analysis was performed on a TA instruments Q500 analyzer at 10 °C/min 
from 25 – 275 °C in a platinum pan under dry nitrogen at 90 mL/min.   Data analysis was collected 
by TA Instruments Universal Analysis 2000 software v4.4A. 
 Ball milling Experiments.   
 Binary Mixtures of AMG 517 with SA, XYL, and MAN.  Physical mixtures of AMG 
517:SA, AMG 517:XYL, and AMG 517:MAN were prepared by weighing the two starting 
materials in different proportions to cover the range of mole fractions needed to prepare the phase 
diagram in 25 – 40 mg sample sizes. The mixtures were transferred to a 1.5 mL Retsch ball jar and 
a 5 mm steel ball was added to each jar.  The ball jars were placed into the Retsch ball mill (Retsch 
Inc., Newton, PA.)   The AMG 517:SA and AMG 517:XYL mixtures were ball milled for 2 
minutes at 15 Htz.  The AMG 517:MAN mixtures were ball milled for 5 minutes at 30 Htz.  The 
samples were then removed and analyzed by XRPD and DSC for analysis.  The AMG 517:XYL 
mixtures analyzed similarly, but TGA analysis was included. 
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The AMG 517/SA Mixtures.  Mixtures were prepared for the AMG 517/SA phase 
diagram by adding AMG 517 or SA to AMG 517/SA.  The compounds were weighed into tared 
aluminum weigh boats and transferred to a 1.5 mL Retsch ball jars and a 5 mm stainless steel ball 
was added before milling (Table 1).  The AMG 517/SA mixtures were ball milled for 2 minutes 
at 15 Htz.  The total mole fraction of AMG 517 in the resulting mixture was calculated as follows 
(Equation 1):  
Mole Fraction =  
mmoles AMG 517
mmoles AMG 517+mmoles of SA
  Equation 1. 
 Organic Solvents Solubility Screen 
 The solubility of AMG 517 was visually estimated in several organic solvents.  AMG 517 
was weighed (5.5 – 5.7 mg) and transferred into 2.5 mL Eppendorf tubes.  Ether, EtOH, acetone, 
THF, and MEK were pipetted (500 uL) into each tube.  CA (5.5 mg) was weighed and added to a 
2.5 mL Eppendorf tube containing AMG 517 and then 500 µL MEK was added. All of the samples 
were labeled and vortexed briefly.  The samples that contained AMG 517 in EtOH and ether and 
ether were cloudy suspensions.  The samples that contained THF, MEK, and acetone were 
solutions.  The sample that contained CA and AMG 517 was also in solution.  The samples were 
then placed on a shaker for 24 hours at 25 ˚C.  The next day, the samples did not change in 
appearance of solubility.  The caps were opened and left on the benchtop to allow solvent to 
evaporate.  However, the sample that contained AMG 517 and ether did not contain any 
recoverable solids.  The remaining solids were analyzed by XRPD. 
 Solvent Evaporation Experiments.   
AMG 517 CA in MEK.  Stock solutions of AMG 517 and CA were prepared in MEK at 
10 mg/mL.  Nine mixtures and two starting material samples were prepared by pipetting different 
volumes of stock solutions into 4 mL vials.  Each sample was vortexed briefly.  All samples,  
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Table 1.  This table summarizes the preparation of AMG 517/SA mixtures for the phase diagram.  
For each sample (Samples 1 – 8) the mole fraction of AMG 517 was determined in two steps.  
First, the number of mmoles of AMG 517 and SA were calculated from the weighed amount of 
AMG 517/SA in the sample, as seen in the left hand side of the table.  Second, SA (top column on 
right) or AMG 517 (bottom column on right) was added to the corresponding amounts of AMG 
517/SA in each sample.  The additions of AMG 517 and SA were converted from mg (column 
third from right) to mmols (second column to right).  Once the total mmoles of each component 
was determined, the mole fraction of AMG 517 for each sample was determined by Equation 1 
and tabulated in the far right column, including the end points, precipitated and were placed on 
bench top stir plates to mix overnight at room temperature.  When the solvent evaporated, the 
remaining precipitate was analyzed by DSC, TGA, and XRPD. 
AMG 517/SA 
(mg)
SA (mg) 
(21%)
AMG 517 (mg) 
(79%)
 SA (mmols) AMG 517 (mmols)  (mg)  (mmol)
Mole Fraction 
of AMG 517
Sample 1 25 5.25 19.75 0.047 0.046 20.66 0.184 0.17
Sample 2 25 5.25 19.75 0.047 0.046 7.7 0.069 0.28
Sample 3 50 10.5 39.5 0.094 0.092 6.9 0.062 0.37
Sample 4 50 10.5 39.5 0.094 0.092 8.27 0.074 0.35
Sample 5 10 2.1 7.9 0.019 0.018 31.73 0.074 0.83
Sample 6 25 5.25 19.75 0.047 0.046 29.75 0.069 0.71
Sample 7 25 5.25 19.75 0.047 0.046 13.22 0.031 0.62
Sample 8 40 8.4 31.6 0.075 0.073 7.93 0.018 0.55
SA Addition
AMG 517 Addition
AMG 517/SA
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AMG 517:XYL in EtOAc.   Mixtures of AMG 517 and XYL were prepared by weighing 
both compounds (0 - 25 mg) into tared aluminum weigh pans on an analytical balance.  The 
compounds were transferred to eleven 4 mL amber vials with screw-top caps.  The vials were 
labeled from 0.0 MF (100% CA) – 1.0 MF (100% AMG 517) to cover the range of compositions 
needed to construct the phase diagram.  EtOAc (3 mL) was pipetted into each sample, the vials 
capped, and vortexed briefly (20 sec).  All of the samples, including 100% XYL and 100% AMG 
517, were suspensions.  The samples were left mixing at 100 rpms.  After 3 days, there was no 
change in the appearance of the samples; all remained suspensions.  The caps were removed and 
the vials were placed in the hood to allow the solvent to evaporate.  The precipitates were analyzed 
by XRPD, DSC, and TGA.  
 
Results and Discussion 
The AMG 517/SA System.   
 The goal of this experiment was to prepare the AMG 517:SA phase diagram by using 
AMG 517 and SA as starting materials and by adding AMG 517 and SA to AMG 517/SA.  The 
mixtures would then be analyzed to determine the eutectic mixtures in the system.  A typical 1:1 
co-crystal phase diagram may contain up to two eutectic mixtures, E1 and E2 (Figure 2) [3, 4, 6]. 
The eutectic mixtures in the system would be identified by the lowest melt of the mixtures that 
occur below the original melts of the starting materials. 
 The AMG 517:SA mixtures were analyzed by XRPD, DSC, and TGA to determine the 
results of mixing the two compounds and then heating the resulting mixtures.   The purpose of the 
XRPD analysis was to detect form changes due to milling.  The mixtures contained AMG 517 and 
SA and no other forms were present (Figure 3). The mixtures prepared for the phase diagram were 
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then analyzed by DSC to compare the melts of the mixtures and to determine if a eutectic mixture 
was present (Figure 4.)  The characteristic melt of SA by DSC analysis indicates that SA melts at 
134 ˚C and TGA shows that it degrades with simultaneous weight loss of 100% (Figure 5).  This 
degradation makes it impractical to determine the two component phase diagram for this system.  
AMG 517/SA may be present in all of the phase diagram mixtures between 0.1 - 0.9 MF, as 
indicated by the broad and shallow endotherm between 168 – 190 ˚C (Figure 3), but the melting 
point of AMG 517/SA has been reported to be 159 °C [1].  The 0.1 – 0.4 MF mixtures contain 
proportionally more SA to AMG 517, which is reflected in the very slight melt depression of SA.   
 The AMG 517/SA system was also studied by a separate method in which the mixtures 
were prepared by adding SA or AMG 517 directly to AMG 517/SA.  The resulting AMG517/SA 
mixtures were analyzed by XRPD and no new forms were found (Figure 6).  All of the mixtures 
contained AMG 517, SA, and AMG 517/SA as contained in the starting materials.  When the 
mixtures were subsequently analyzed by DSC, hermetically sealed pans were chosen initially to 
limit chemical degradation products of SA.  However, the characteristic melt and resulting 
endotherms of AMG 517/SA was not reproduced in hermetically sealed pans, and so open DSC 
pans were used (Figure 7).  The following change in melting temperature of the resulting broad 
shallow endotherm of the SAC melt at 159 °C was used to determine the effect of the addition of 
AMG 517 and SA to AMG517/SA mixtures (Figure 7).  In this example, using AMG 517/SA as 
a starting material was critical in the preparation of the phase diagram.  Only after adding SA and 
AMG 517 to AMG 517/SA were the eutectic mixtures (E1 and E2, Figure 8) were observed and 
the liquidus lines revealed.  Even with subsequent degradation, clear eutectics can be observed in 
this case (E1 and E2, Figure 8).  The liquidus line SA and AMG 517, respectively.  This indicates 
a melting point depression of ~ 60 °C for E1 relative to the melting point of AMG 517.  E2 melts  
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Figure 2.  An idealized 1:1 co-crystal phase diagram, where the vertical dotted line delineates the 
diagram at the 0.5 MF co-crystal mixture and the melting temperature of the co-crystal (Tcoc.).  The 
x-axis is plotted by the composition of A:B mixtures with increasing amounts of compound B to 
compound A from left to right of the diagram.  The y-axis is the temperature of the mixtures, with 
increasing heat up the axis.  TA and TB is the melting temperature of pure A and B, respectively.  
TE1 and TE2 is the melting temperature for each eutectic mixture and becomes the solidus boundary 
for the corresponding side of the diagram.  E1 and E2 indicate the composition of the eutectic 
mixture at the eutectic temperature.  The solidus boundary is the minimum temperature of the 
mixtures melting.  Beneath the solidus, compounds A and B are solid.  Above the solidus 
temperature, one of the compounds begins to melt.  The liquidus curve is the boundary between 
both compounds melted (above the curve) and one compound melted and the other is solid (below 
the curve).  The liquid phase contains both components melted.  Solid A/B + Liquid is a mixed 
phase of solid A/B and melted A/B, depending on which side of the co-crystal the mixture 
composition is located on the x-axis [4, 6, 7]. 
 
45 
 
 
 
 
 
  
 
 
Figure 3.  Physical mixtures of AMG 517 and SA prepared to determine the phase diagram were 
analyzed by XRPD.  The intensities of the peaks are relative to the mixtures and not to scale.  All 
of the mixtures of AMG 517 and SA (0.1 – 0.8 MF, trace second to the top to trace second to the 
bottom) contain all of the peaks of each compound, therefore there are no new forms.  The 0.5 MF 
mixture does not contain any peaks unique to AMG 517/SA and is a physical mixtures containing 
peaks of AMG 517 and SA. 
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Figure 4.  Thermogram of a DSC overlay of the AMG 517:SA mixtures prepared for the phase 
diagram as analyzed in open DSC pans.  The 0.1 – 0.4 MF mixtures (traces second to the top – 
fifth from the top) show degradation after the melt of SA (130 – 160 ˚C), followed by the melt of 
AMG 517/SA (160- 180 ˚C), and the melt of AMG 517 (onset melt at 223 ˚C).  The 0.4 MF 
mixtures contain proportionally more SA to AMG 517, which is reflected in the very slight melt 
depression of SA.   The 0.5 MF mixture contains AMG 517/SA and the melt is shifted to a higher 
temperature due to some AMG 517 in the mixture did not convert to the co-crystal.  The 0.6 – 0.8 
MF mixtures include the AMG 517/SA melt (160- 190 ˚C) and the melt of AMG 517 (223 ˚C).   
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Figure 5.  The onset melt of SA is analyzed by DSC (green trace, top) and the weight loss evaluated 
by TGA (blue trace, bottom) at 10 °C/min.  It has an onset melt of 134 °C and experiences 99% 
weight loss before 170 °C.  
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Figure 6.  XRPD overlay of AMG 517 (red trace on bottom,) AMG 517/SA (middle blue trace,) 
and SA (top green trace) with mixtures of AMG 517/SA (middle blue trace) with added AMG 
517 and SA.  The graph is structured with increasing amounts of AMG 517 added to the mixtures 
moving down y-axis.  The intensities of the peaks are relative to each other and are not to scale. 
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slightly above the onset melt of AMG517/SA at 175°C, and may not be a eutectic of AMG 
517/SA, but rather a eutectic melt of AMG 517 (original onset melt 223 – 228 °C). 
The AMG 517 Mannitol Binary System 
 When the mixtures of AMG 517:MAN were heated and analyzed by DSC, it was apparent 
that there was very little mixing between the two compounds (Figure 9).  The physical mixtures 
did not exhibit a melt depression of either compound when heated.  The melt of MAN is shown at 
the top of the thermogram (top green DSC trace,) and the mixtures proportionally increase in AMG 
517 and reduce in MAN until pure AMG 517 is indicated at the bottom of the figure (bottom blue 
DSC trace, Figure 9.)  All of the mixtures contain two melts, indicative of each compound, that 
occur at different ends of the temperature range.  The original melts of the compounds changed 
very little with the presence of either compound in the mixture. 
The AMG 517/CA system 
 AMG 517/CA is a known co-crystal and expansion of the phase diagram was attempted 
by the solvent evaporation method.  An organic solubility screen of AMG 517 and CA was 
designed to determine a suitable solvent for the mixing experiment.  The organic solubility of 
AMG 517 and CA were visually determined in several solvents.  Then, when a solvent was 
descends from the AMG 517/SA up to each eutectic and is traced back to the melting point of 
decided upon, a series of mixtures were prepared to construct the phase diagram.  XRPD analysis 
was utilized to characterize the solids resulting from the preparations.   
  Organic Solubility Screen.  The purpose of the organic solubility screen was to identify 
a solvent where the solubilities of AMG 517 and CA were similar and which gave the stable 
polymorph of each of the compounds. The solubilities of AMG 517 were estimated in ether, EtOH, 
acetone, THF, and MEK.  The solubility of CA was only estimated in MEK (Table 2).  Several of 
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Figure 7.  Comparison of DSC analysis of AMG 517/SA in open DSC pans (green trace, top) and 
hermetically sealed DSC pans (blue trace, bottom.)   
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Figure 8.  The DSC thermograms of the mixtures of AMG 517, SA, and AMG 517/SA are shown 
with increasing amounts of AMG 517 from top to bottom of the thermogram.  The 0.17 – 0.37 MF 
mixtures may contain degradation products of SA, and AMG 517/SA, and AMG 517.  The 0.55 - 
0.83 MF mixtures melt contain AMG 517/SA melting at temperatures above the onset melt of 
AMG 517/SA.  E1 and E2 are identified as the eutectic mixtures in the AMG 517/SA system due 
to the depressed melt. 
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Figure 9.  DSC traces of physical mixtures of AMG 517 and MAN analyzed in hermetically 
sealed DSC pans.  There is very little change in the onset melt of either component. 
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the XRPD patterns of the solids remaining after the organic solubility screen indicate the presence 
of new form are shown in Figure 10.  AMG 517 appears to form a solvate in THF (second from 
bottom, Figure 10).  The precipitates of both AMG 517 and CA from MEK match their respective 
starting forms.  MEK was chosen as the solvent for subsequent solvent evaporation work.   
 Solvent Evaporation Experiment.  Mixtures used to prepare the phase diagram were 
analyzed by DSC (Figure 11).  As more AMG 517 is added the CA melt is depressed from 134 to 
130 °C (Figure 11).  Also, the AMG 517/CA melt is not identified due to the degradation of CA.  
The 0.5 MF mixture, which is composed of a 1:1 stoichiometric mole ratio AMG 517:CA, melts 
at onset temperature associated with AMG 517/CA.   The 0.5 MF mixture, which is composed of 
a 1:1 stoichiometric mole ratio AMG 517:CA, melts at onset temperature associated with AMG 
517/CA.   As more AMG 517 was added the resulting melts are actually shifted to a higher 
temperature, possibly indicating a peritectic system [4, 6, 7].  A eutectic mixture with a slightly 
lower melting point than CA may be present in the CA rich mixtures, but precise determination of 
its composition was not possible. 
 Further investigations were conducted to determine if other forms are present in the 
precipitates after the mixing of the two compounds during the solvent evaporation experiment.  
The mixtures prepared for the phase diagram  from the AMG 517 CA solvent evaporation 
experiment were also analyzed by XRPD before DSC analysis (Figure 12).  All of the mixtures 
contained multiple forms, such as the solvate of AMG 517 in MEK (AMG 517 MEK), CA, and 
AMG 517/CA.  The AMG 517 MEK XRPD pattern was not present in the organic solubility 
screen (Figure 10), which indicates that the solvate may not always form.  However, the pattern 
was present in some of the resulting mixtures.  The presence of AMG 517/CA was detected in 
most mixtures that contained a peak at 20.2˚ 2θ, such as the 0.4 MF mixture (arrow, fifth trace  
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Table 2.  Solubilities of AMG 517 in several solvents were estimated by the visual appearance of 
the sample (suspension/solution).  The solubility of CA was only estimated in MEK. 
  
Estimated solubilities of AMG 517 and CA in organic solvents 
Compound  Ether EtOH acetone THF MEK 
AMG 517 no precipitate 
< 11 
mg/mL 
> 11 
mg/mL 
> 11 
mg/mL 
> 11 
mg/mL 
CA n/a n/a n/a n/a > 11 mg/mL 
55 
 
 
 
 
 
 
 
Figure 10.  Overlay of XRPD patterns from the isolated materials during the organic solubility 
screen with AMG 517 in MEK, Acetone, and THF.  The isolated material of CA evaporated from 
MEK is also compared to CA (CA Ref, top trace).  New peaks, as indicated by the arrows, were 
found in the AMG 517 THF precipitate and the AMG 517 MEK precipitate (trace second from 
bottom.)  AMG 517 in acetone (middle trace) had an insufficient amount of sample to obtain a 
clear scan of the precipitate. 
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from the top, Figure 12).  The XRPD powder patterns of the α- and β- polymorphs of CA (α-CA 
and β-CA) and AMG 517/CA were also compared to the resulting precipitates of the physical 
mixtures to identify the forms contained in the mixtures [14 – 16].  These unknown forms were 
not compared to the CA γ-polymorph because a crystallized pattern was not available for 
comparison in the Cambridge Structural Database (CSD) [17]  nor in a literature search. 
 The 0.4 MF, 0.5MF, and 0.8 MF mixtures were analyzed more closely to identify the forms 
present in the mixtures.  The 0.4 MF mixture was expected to contain CA and AMG 517 as 
determined by DSC analysis.  The XRPD diffractogram of the 0.4 MF mixture contained AMG 
517, AMG517/CA, α-CA, and CA MEK (Figure 13).  The 0.5 MF mixture was expected to form 
AMG 517/CA.  However, the XRPD data showed the presence of AMG 517 MEK, AMG517/CA, 
and α-CA present (Figure 14).  The 0.8 MF mixture was expected to contain the depressed melt 
of AMG 517/CA due to prior DSC analysis (Figure 15).  However, the XRPD analysis showed 
the mixture contained AMG 517 MEK, α-CA, and AMG 517/CA.  In conclusion, there may be a 
eutectic mixtures found in the AMG 517/CA system, but XRPD analysis showed multiple forms 
present in the mixture.   
AMG 517 Xylitol System 
Mixtures of AMG 517 and XYL were prepared by ball milling and solvent evaporation 
and analyzed by XRPD and DSC (Figures 16 and 17).   
Ball Milling Experiment.  XYL was ball milled with AMG 517 because of the low 
melting temperature of XYL (onset melt at 92 ̊ C), and the thermal stability of the compound when 
melted to higher temperatures [12].  The melt of XYL is characterized by a sharp melt and weight 
loss occurs at temperatures > 200 ˚C (35 % weight loss by 275 ˚C) (Figure 18). Therefore, XYL 
should not degrade at or below the melting temperatures of AMG 517 (onset melt at > 220 ˚C.)   
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Figure 11.  Overlay of DSC traces for AMG 517:CA solvent evaporation experiment in MEK.  
The melting temperature of CA and AMG 517 are indicated by vertical lines.  The mixtures 
composition is indicated on th left.  The 0.1 – 0.4 MF mixtures show the CA melt and 
subsequent  degradation products may be present.  The 0.5 MF mixture has an onset  melt at 209 
°C as expected for AMG 517/CA.  The phase diagram is outlined in red.  E1 is the possible 
eutectic composition in the CA rich portion of the phase diagram.   
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Figure 12.  XRPD patterns of the mixtures prepared for the AMG 517/CA phase diagram with 
increasing amounts of AMG 517 added to the mixture moving down the figure.  Some of these 
peaks also match the XRPD diffractogram of AMG 517 MEK precipitate (green trace, second 
from bottom), which is indicative of the presence of a solvate.  Multiple forms have been idenitifed 
in most of the mixtures that include AMG 517, CA, α-CA, AMG 517/CA, and AMG 517 MEK. 
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The physical mixtures of AMG 517:XYL show two melts that correspond to the original 
compounds and no eutectics (Figure 19).  No indication of degradation after XYL melting was 
observed.  The XRPD diffractograms of the mixtures indicate only the presence of AMG 517 and 
XYL (Figure 20).  Solvent evaporation experiments were designed to increase mixing between the 
compounds.  
 Solvent evaporation in EtOAc.  The DSC overlay of the AMG 517:XYL samples 
indicate a melting depression of XYL as more AMG 517 is added, resulting in a depressed melt 
of XYL in the 0.5 MF mixture at 88 ˚C (Figure 21.)  The 0.5 MF mixture also contains the most 
depressed melt of XYL at 88 ˚C, but is not considered a eutectic mixture.  This is due to the 
definition of a eutectic mixture, which contains only one melt, and the 0.5 MF mixture contains a 
separate melts for both compounds [4, 5].  This is in contrast to a co-crystal phase diagram where 
two eutectic melts can be observed [5, 6].  In between the 0.8 – 0.9 MF mixtures, the melt of XYL 
is not detected by the DSC and the melt of AMG 517 is not depressed.  The melts of the mixtures 
were also compared to the onset melts of AMG 517/XYL from a HTS screen and was not 
comparable (onset melts at 98.2 ˚C and 213 ˚C) (Figure 17).  The 0.5 MF mixture was analyzed 
by DSC and TGA in order to more fully characterize the mixture (Figure 22).  At 80 ˚C, XYL 
melts and solvent is boiled away as signified by the simultaneous weight loss of 3.6 %.  The 
depressed melt of AMG 517 occurs at 200 ˚C with a simultaneous weight loss of 22%.  
 The XRPD patterns of the mixtures contain multiple forms (Figure 23) do not show gradual 
increase of AMG 517 across the samples, nor do they indicate that AMG 517/XYL is present in 
the samples.  In some specific diffractograms, 0.5 MF for example (Figure 24), the corresponding 
peaks do not match any known forms of AMG 517, AMG 517/XYL, or XYL.  This apparent 
phase heterogeneity and the observed lack of eutectic mixture formation justified no further work  
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Figure 13.  The 0.4 MF mixture contained multiple forms.  The mixture (0.4 MF, top trace) is 
compared to AMG 517/CA (second from top), β-CA (middle),  α-CA (second from bottom), and 
CA MEK (bottom trace).  The mixture contains multiple forms as indicated by the peaks that are 
labeled by diffractography angle 2θ.  None of the peaks matched β-CA. 
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Figure 14.  The 0.5 MF mixture (top trace) was compared to AMG 517/CA (bottom trace,) β-CA 
(second from bottom), AMG 517 MEK (middle), and α-CA (second from top.)   The 0.5 MF 
mixture contained multiple forms including AMG 517/CA, α-CA, and AMG 517.  
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Figure 15.  The XRPD patterns of the 0.8 MF mixture (top) is compared to α-CA (second from 
top), AMG 517 MEK (middle), β-CA (second from bottom), and AMG 517/CA (bottom.)  The 
mixture contained multiple forms.  
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Figure 16.  XRPD overlay of AMG 517 (top purple trace,) XYL (middle red trace), and AMG 
517/XYL (bottom blue trace.)   
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Figure 17.  DSC trace of AMG 517/ XYL obtained from HTS.   
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Figure 18.  DSC (top, blue trace) and TGA (bottom, green trace) of XYL. 
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Figure 19.  Physical mixtures of AMG 517:XYL prepared by ball milling.  Very little shifting in 
melting temperature of the mixtures was attributed to added compounds in the mixture. 
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Figure 20.  Ball milled mixtures of AMG 517 and XYL did not show the presence of any unknown 
forms after XRPD analysis. 
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Figure 21.  AMG 517 and XYL mixed in EtOAc are analyzed by DSC in hermetically sealed 
DSC pans. As more AMG 517 is added to the mixture, the corresponding endotherm (220 – 223 
°C) becomes deeper. 
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Figure 22. The DSC/TGA overlay of the 0.5 MF mixture contains the depressed melt and weight 
loss of XYL (90˚C) and AMG 517 (200 ˚C).  The TGA shows a simultaneous weight loss of 3.6 
% which is not the expected weight loss of XYL at 81 ˚C, and so the form may be a solvate of 
EtOAc.  The 8.4% weight loss between 100 – 200 °C that may be due to degradation of XYL.  
The melt of AMG 517 at 200 ˚C is accompanied by a weight loss indicative of chemical 
degradation.  
  
70 
 
 
 
 
 
 
 
 
 
Figure 23.  XRPD traces of all of the AMG 517 XYL mixtures in EtOAc.  As more AMG 517 is 
being added to the mixtures, the peaks of AMG 517 become more pronounced.  The arrows in 0.1 
MF and 0.5 MF mixtures (second from top trace and sixth from top trace, respectively) highlight 
peaks of a new form that that also appear in some of the other mixtures. 
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Figure 24.  XRPD patterns of the AMG 517 XYL COC (COC, top) compared to XYL (XYL, 
second from top), 0.5 MF mixture (red, second from bottom), and AMG 517 (AMG 517, bottom.)  
The 0.5 MF mixture contains AMG 517 (arrow at matching peak at 6.7 ̊ ), unknown peaks at 11.3˚, 
11.9˚, and 26.2˚, and XYL (arrows of matching peaks at 33.4˚, and 37.8˚ 2θ). 
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on this system. 
Conclusions. 
 The purpose of this work was to use DSC analysis of AMG 517 mixtures to prepare binary 
phase diagrams and investigate the presence of a eutectic mixture.  Only when AMG 517/SA was 
used as a starting material for the AMG 517:SA phase diagram were potential eutectic mixtures 
observed.  It is doubtful, however, that the presence of degradation would still be able to consider 
these eutectic mixtures as true eutectics, since degradation should not be detected.  Also, it is 
important to consider that chemical degradation upon heating confounds interpretation of the data 
to some extent. 
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Chapter 4. Glipizide Binary Systems   
 Introduction.  Glipizide is a popular second generation sulfonylurea drug used extensively 
to complement other treatment and manage the disease Type II diabetes [1, 2].  The small moleclue 
is a weak acid (pKa = 5.9), which is practically insoluble in water (1.4 μg/mL) and in acidic 
environments (Figure 1) [2, 3].  Glipizide is categorized by the Biopharmaceutical Classification 
System (BCS) as a class II drug with high permeability and low soubility, resulting in dissolution 
rate limited bioavailability [2 – 4].  The pH-solubility profile displays a sharp rise in aqueous 
solubility above the pKa [5].  A eutectic mixture may be able to address low aqueous solubility 
and a slow dissolution rate in acidic aqueous environments [5, 10].  In this work, glipizide and 
other small molecules were ball milled to prepare physical mixtures that were studied by DSC.   
The melts of the mixtures were plotted to construct phase diagrams and find the eutectic mixtures 
[6 – 8, 10, 12].  
 
 
 
 
 
 
Figure 1.  Chemical structure of glipizide (445.5 MW) [13]. 
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Experimental 
Materials.  Glipizide (G) was purchased from Alexis Biochemicals [13].  2-
Chloroacetamide (2CA) was purchased from Fluka [14].  Propionamide (PA), benzamide (BAD), 
succinamide (SU), and adipamide (ADA) were obtained from Sigma Aldrich [15 – 18].  D-
glucamide (GA), n-capronamide (n-CAP), and crotonamide (CRT) was purchased from TCI [19 
– 21].  Anhydrous citric acid (ACA) was purchased from JT Baker [22].  Methanol (MeOH) was 
purchased from JT Baker.  All compounds were used as received.   
Ball milling Experiments. 
Mixtures containing G and ADA, 2-CA, GA, SU, BAD, n-CAP, CRT, PA, or ACA were 
weighed and transferred to 1.5 mL Retsch ball jars (Table 1.)  Mixtures prepared for the phase 
diagrams were prepared as mole fractions (MF) of G to the amide [23].  The ball jars were 
assembled, tightened, and placed onto the Retsch ball mill.  The ball jars were agitated for 2 
minutes at 30 Htz.  The ball jars were removed from the mill, and the samples were recovered and 
analyzed by PXRD and DSC. 
Thermal Analysis Methods 
Differential Scanning Calorimetry (DSC) measurements were performed on a TA 
Instruments Q100 calorimeter (New Castle, DE).  All mixtures were weighted into hermetic pans 
and the pans were sealed prior to being placed in the DSC.  Samples were equilibrated at 25 °C 
then ramped to 300 °C at 10 °C/min.  
Thermal gravimetric analysis (TGA) was performed on a TA Instruments Q500 analyzer 
at 10 ºC/min from 25 ˚C to 275 ºC in a platinum pan under dry nitrogen at 90 mL/min.  Data 
analysis was accomplished with TA Instruments Universal Analysis 2000 software v4.4A.  
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Compounds Onset melt (˚C) 
Glipizide 213-5 
ADA 227 
2-CA 115 
GA 126 
SU 207 
BAD 125 
n-CAP 101 
CRT 159 
PA 80 
ACA 153 
 
Table 1.  Experimentally determined onset melts of amides determined during the G amide 
screen.  Amides were weighed into hermetically sealed DSC pans and heated at 10 °C/min. 
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X-Ray Powder Diffractometry Method 
X-ray diffraction patterns (XRPD) were obtained on a PANalytical X’Pert PRO X-ray 
diffraction system (Almelo, the Netherlands).  Samples were scanned in continuous mode from 5-
45 º (2θ) with step size of 0.0334 º on a spinning stage at 45 kV and 40 mA with CuKα radiation 
(1.54 Å).  The incident beam path was equipped with a 0.02 rad soller slit, 15mm mask, 4 º fixed 
anti-scatter slit and a programmable divergence slit.  The diffracted beam was equipped with a 
0.02 rad soller slit, programmable anti-scatter slit and a 0.02 mm nickel filter.  Detection was 
accomplished with an RTMS detector (X’Celerator).   
 
Results and Discussion. 
Glipizide-Amide Screen.  The purpose of the screen was to determine which G-amide mixture, 
prepared in a 1:1 stoichiometric ratio, would have the greatest melting depression for G; 
degradation on melting was also noted. (Table 2) [10, 11]. The melt of the mixtures were compared 
to that of G which melts at 215 °C with degradation and limited degradation would be carried 
forward for full expansion of the phase diagram.  
In most of the mixtures, the melt and subsequent degradation of the samples obscured the 
melt of G by DSC analysis (Figure 3).  For example, G:n-CAP (dashed green trace, third from 
bottom) and the G:CRT mixture (red dash trace, second from bottom) (Figure 3) both degrade 
starting around 175 °C.   In the G:ADA mixtures, the presence of ADA depressed the melt of G 
to around 200 ˚C, which is 14 ˚C below the original melt of G (Figure 3, second from top trace.)  
As mentioned previously, ADA melts at a higher temperatures than G.  Therefore, more G:ADA 
mixtures were prepared in order to construct the phase diagram.  Degradation is minimal in the 
G:ADA mixtures and the G:PA mixtures.  PA was also chosen to prepare mixtures to develop a 
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* The G melt was indiscernible due to degradation. 
 
Table 2.  The results of the 1:1 glipizide amide screen.  Most of the mixtures had degradation, 
which obscured the G melt in the DSC analysis [13, 22].  The G:ADA mixture did not seem to 
indicate degradation by DSC analysis. 
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Figure 2.  DSC (bottom) and TGA (top) overlay of G that was ball milled for 2 minutes at 30 Htz, 
and analyzed in a hermetically sealed DSC pan.  G has an onset melt at 215 °C where it loses 24 
% of its weight. 
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Figure 3.  The DSC thermogram of 1:1 physical mixtures of G (top trace) and amides as analyzed 
in hermetically sealed DSC pans.  Degradation is apparent in most of the mixtures. 
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phase diagram because the mixture (Figure 1, bottom dashed trace) also results in a melt depression 
of G (~10 °C to 200 ˚C) and a minimal amount of degradation.    
Glipizide ADA Binary System 
 Mixtures were prepared to construct a phase diagram for G:ADA with a goal to identify 
the eutectic mixture which would have the lowest melting point.  DSC/TGA analysis of the starting 
materials show that ADA melts 15 °C above G.  Both compounds melt and degrade simultaneously 
(Figure 4).   The G:ADA  mixtures were analyzed by XRPD and the resulting data verified that 
the forms of G and ADA were unchanged after the ball milling process (Figure 5).   
The physical mixtures were then analyzed by DSC to determine the melts needed to prepare 
a composition-temperature phase diagram (Figure 6).  As more G is added to the mixture, the melt 
of G is depressed and shifts below 200 °C (curved, Figure 6).  The 0.65 MF G:ADA mixture has 
a single symmetrical melt that occurs at the lowest melting temperature.  Therefore, this mixture 
may be considered a eutectic mixture.  The mixtures between 0.1 – 0.55 MF have the characteristic 
melt of a physical mixture signified by the resulting asymmetrical double peaks.  The double peaks 
signify the mixture contains a MF mixture (green trace, third from bottom) begins to degrade and 
experience weight loss at lower temperatures than the 0.55 MF mixture (blue trace.)  Also, the 
0.45 MF and 0.55 MF mixtures experience melting and weight loss simultaneously. In either case, 
the mixtures are not thermally stable and there is degradation in both mixtures. 
Glipizide PA Binary System 
 The presence of a G:PA eutectic mixture was investigated.   The physical mixtures of G 
and PA were prepared by ball milling.  The melting behavior of these mixtures were consistent 
with a monotectic system. G:PA mixtures were analyzed by XRPD and DSC.  The XRPD analysis 
indicated that the mixtures contained the original compounds and no other forms (Figure 8).  The 
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Figure 4.  Overlay of DSC and TGA of ADA (top pair, green trace) and G (bottom pair, blue 
trace.) DSC samples were analyzed in hermetically sealed pans at 10°C/min for both 
components. 
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Figure 5.  The physical mixtures of G (bottom trace) and ADA (top trace) contain the two 
original compounds and no new forms.  The amount of G increases in the mixtures from the top 
(100% ADA) to the bottom (100% G) in the XRPD diffractograms. 
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Figure 6.  DSC traces for G:ADA mixtures show the gradual effect of proportionally added 
G:ADA on the melting temperature of the mixture. As more G is added to the mixtures, moving 
down the thermogram, the eutectic melt is formed at 189 ˚C in the 0.65 MF mixture.   
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DSC data shows that the melting point of G drops with addition of PA.  The mixtures in the 
monotectic system are characterized by melting point depression for the higher melting compound, 
G, and unchanged melting point for the lower melting compound, PA [9].   In all of the mixtures, 
the melting point of PA is minimally affected by the increasing amount of G in the mixture, but G 
is depressed by the large amount of PA in the mixture (Figure 9).   
 As seen in the other amide mixtures that include G, degradation is a concern when 
preparing eutectic mixtures by the fusion method.  The 0.5 MF G:PA mixture was analyzed by 
DSC and TGA in a closed DSC pan (Figure 10) to determine if degradation was occurring.  The 
0.5 MF mixture has an initial onset melt of 70˚ C and a simultaneous weight loss of 13%, 
corresponding to the loss of PA.  The mixture then melts again at 163 ˚C with a subsequent weight 
loss of 29%.  Because weight loss is occurring during melting, the composition of the mixture is 
changing during the melt, either by sublimation or degradation, therefore no further investigation 
was pursued. 
Conclusions 
The depressed melts of G was only observed in a few systems (Table 4).  The depressed 
melts of G were lowest in the 0.65 MF G:ADA mixtures, and may be considered a eutectic 
mixture.  The thermal degradation of G was observed in all systems evaluated and the production 
of degradants from the API and/or the amide confounded data interpretation.   
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Figure 7. The 0.45 MF and 0.55 MF G:ADA mixtures were analyzed by DSC (open pans) and 
TGA.  The multiple weight loss is due to ADA and G melting and forming separate degradants. 
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Figure 8.  The physical mixtures of G:PA  prepared by ball milling.  All of the mixtures contained 
the original compounds and no other forms. 
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Figure 9. DSC overlay of ball milled mixtures of G:PA.  Top trace (green) and bottom trace 
(black) are propionamide and glipizide, respectively, starting materials.  The DSC traces are 
relative to each other with samples with the most propionamide at the top of the graph least amount 
at the bottom. 
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Figure 10.  The 0.5 MF G:PA mixture was analyzed by DSC (blue trace, bottom) and TGA (green 
trace, top).  Weight loss occurs simultaneously during melting, producing degradation products as 
indicated in the figure. 
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Table 4.  Mixtures prepared for the phase diagrams of the glipizide systems are summarized.  A 
eutectic in the G:ADA mixtures was found, and but then the mixture degraded with increasing 
temperature.  
 
 
 
 
 
 
 
 
 
  
System COC? Eutectic Mixture Melt (˚C) Further Analysis? Future Plans
Glipizide ADA No  0.65 MF Mixture 189 No, Degradation Present Solvent Evap, Hybrid Method
Glipizide PA No No N/A No, Degradation Present Solvent Evap, Hybrid Method
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Chapter 5.  Naproxen Vanillin Binary System 
 
 Introduction.  Utilizing a eutectic mixture as a crystalline solid dispersion is a strategy to 
improve the solubility or change the intrinsic dissolution rate of a drug [1 -7].  The poorly soluble 
compound naproxen (NAP) and the highly aqueous soluble compound vanillin (VAN) were 
prepared in mixtures of varying proportions to form a phase diagram.  The molecular structure of 
NAP and VAN, and some physicochemical properties, are listed in Table 1. 
NAP is an example of a BCS class II drug that has poor solubility and high permeability 
[8].   The drug is a non-steroidal anti-inflammatory drug (NSAID) characterized by poor 
wettability and low aqueous solubility [11].  The mechanism of action of NAP is through the 
inhibition of the enzyme cycloxygenase (COX) in the inflammation pathway [12 – 13].  NAP is a 
weak acid (pKa of 4.2) [14], has poorly aqueous solubility (27 mg/L at 25 ˚C) [15],  and a melting 
point of 153 - 156 °C [10].  A eutectic mixture of NAP and VAN was investigated as a strategy to 
increase solubility [6, 15]. 
 VAN was selected because previous studies have shown that the compound forms a 
eutectic mixture with other compounds, such as p-anisidine [16].  VAN was also a practical choice 
because the compound is a member of the Everything Added to Food in the United States (EAFUS) 
by the U.S. Food and Drug Administration [17].  VAN is safe to handle and freely water soluble 
(10 mg/mL) [18].  VAN is weakly basic with a pKa of 7.8, and melts between 81 - 83 °C [18 – 
20].  Samples were prepared to determine the phase diagram for NAP and VAN by the fusion 
method [4, 15, 20 – 22].  The mixtures were analyzed by DSC, and then the melts recorded on the 
phase diagram.  The eutectic mixture is identified as the mixture that exhibited the lowest melt [4, 
5, 20 – 22]. 
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Table 1.  Some physicochemical properties and molecular structures of NAP and VAN [10, 18]. 
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Experimental 
Materials.  NAP (Sigma Aldrich) and VAN (Alfa Aesar) were used as received.  1-
Methyl-2-pyrrolidone (NMP) (Sigma Aldrich), dimethyl sulfoxide (DMSO) (Sigma Aldrich), 
ethanol (EtOH) (Pharmco), acetonitrile (MeCN) (Sigma Aldrich), ethyl acetate (EtOAc) (Burdick 
& Jackson), methanol (MeOH) (Sigma Aldrich), toluene (Burdick & Jackson), and n-heptane 
(Burdick & Jackson) were obtained from Fischer Scientific.  Dulbecco’s Phosphate Buffered 
Saline (PBS) was obtained from Sigma Aldrich and stored on bench top.  VAN was stored at 
refrigerated temperatures and NAP was stored on the bench top. 
Organic Solubility Screen.  The solubilities of NAP and VAN were determined in several 
organic solvents.  A series of Eppendorf tubes (2.5 mL) were labeled by organic solvent and 
whether the tube contained of NAP or VAN.  NAP and VAN were weighed (1.5 – 2.5 mg) and 
transferred to Eppendorf tubes.  NMP, DMSO, EtOH, MeCN, EtOAc, MeOH, toluene, and n-
heptane were pipetted (250 μL) into each tube.  Vials were capped and placed into a shaker at 25 
°C for 24 hours to allow the samples to equilibrate.  The next day, the NAP samples were solutions 
and the VAN samples were suspensions.  The samples were removed from the shaker, and then 
transfer pipets were used to add 0.2 mL of each sample into the labeled 0.2 μm PTFE filter insert 
attached to an Eppendorf tube.  The caps were closed, the samples were centrifuged and spun at 
25000 rpm for five minutes.  The solubility of the filtrates were analyzed by HPLC-UV. 
Ball Milling Experiment.  NAP:VAN mixtures were prepared for a phase diagram  by 
weighing the compounds in different proportions and then transferring into 1.5 mL Retsch Ball 
jars.  A 5 mm stainless steel ball was added, and the jars were assembled and placed in the Retsch 
ball mill (Retsch, Inc. Newton, PA).  The mixtures were milled for 2 minutes at 15 Htz, and then 
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analyzed on DSC, TGA, and XRPD.  For the phase diagram, the melts were determined by a single 
mixture by DSC analysis. 
Aqueous solubility experiment of naproxen and 0.11 MF NAP:VAN mixture.  The 
solubilities of the eutectic mixture and the original drug were compared in DI Water and PBS at 
25 ºC and 37 ºC.  NAP was weighed into 20 mL scintillation vials for DI Water (8.5 mg) and PBS 
(34 mg) for 25 ºC and 37 ºC.  The 0.11 MF NAP VAN (11% NAP/ 89% VAN) eutectic mixture 
was prepared by the fusion method.  The eutectic mixture was prepared in duplicate for DI Water 
solubility testing by weighing NAP (8.5 mg) and VAN (45 mg) into two 1.5 mL Retsch ball jars.  
The mixtures prepared for PBS solubility measurements were prepared by weighing NAP (17 mg) 
and VAN (90 mg) into 4 Retsch ball jars.  The jars were combined to form mixtures of 34 mg 
NAP and 180 mg VAN.  All of the samples were agitated for 2 minutes at 15 Htz.  The mixtures 
prepared for DI Water and PBS solubility measurements were transferred to 20 mL scintillation 
vials labelled by NAP, eutectic mixture (EM), and each heating condition.  The eutectic mixtures 
was prepared by forming a solid dispersion by heat on an IKA heated stir plate with a digital 
thermometer.  The vials were set to heat from ambient conditions to 68 ˚C while mixing at 400 
rpm.  All of the mixtures melted into clear viscous solutions in < 5 minutes.  The samples were 
immediately placed into an ice bath and left to cool completely for 2 – 3 hours.  When completely 
cooled, the mixture hardened into a white solid mass.  This heating and cooling process was 
repeated three times.  The mixtures were broken up by a spatula and analyzed by XRPD.   
The solubilities of NAP and 0.11 MF NAP:VAN mixture were determined from slurries 
in DI water or PBS (pH 6.8) at 37 °C or room temperature.  DI Water (15 mL) or PBS (15 mL) 
were pipetted into the designated sample vial and a stir bar was added (400 rpms).  This created 
saturated slurries of NAP in DI Water (0.5 mg/mL) and PBS (2.2 mg/mL).  After 48 hours, the pH 
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of the suspensions were measured.  Photomicrographs (200 x magnification) were recorded and 
compared.  The samples were aliquotted in triplicate, by syringe, and filtered through 0.45 um 
PTFE 13 mm Acros filters.  The first 5-7 drops of the filtrate were discarded to avoid any effect 
of filter binding.  Concentrations were determined by HPLC-UV.  Finally, remaining solids were 
isolated by filtration and characterized by PXRD.  
Freeze-Thaw Stability.  Stability during freeze-thaw cycling was evaluated for 0.11 and 
0.8 MF NAP:VAN mixtures.  For the 0.11 MF NAP:VAN sample, 8.5 mg NAP and 45 mg of 
VAN along with a single steel bearing were added to each of three 1.5 mL Retsch ball jars. 
Similarly, a 0.8 MF NAP:VAN sample was prepared using 43 mg NAP and 7 mg VAN.  The ball 
jars were loaded into the mill and agitated for 2 minutes at 15 Hz.  The contents of each ball jar 
were separated from the bearings and transferred to 4 mL screw toped vials along with Teflon 
coated stir bars.  The vials were placed on a heated stir plate and heated to 68 °C and 150 °C for 
the 0.11 and 0.8 MF mixtures, respectively.  All samples formed clear viscous liquids upon 
melting. The samples were placed in ice baths to freeze, and then the freezer overnight.  One of 
the 0.11 and the only 0.8 MF NAP:VAN samples were analyzed by microscopy, DSC and HPLC-
UV. The freeze-thaw cycling was repeated one and two more times for the remaining 0.11 MF 
NAP:VAN samples, after which the samples were characterized.  
HPLC-UV samples were prepared by weighting 1.3 mg of each solid dispersion was 
weighed into a 20 mL scintillation vial.  DMSO (20 mL) was pipetted directly into the vial.  The 
vials were placed into a Branson sonic bath for 15 minutes to dissolve the samples, vortexed 
briefly, and the samples pipetted directly into HPLC vials. 
Photomicroscopy.   Polarized light microscopy (PLM) photomicrographs were taken 
using a Nikon LV100 polarized light microscope, equipped with a Nikon Digital Camera DS-Fi2, 
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operated by NIS Elements D software.  Samples were placed on microscope slides, protected with 
a cover slip, and then analyzed at 200x magnification. 
High Pressure Liquid Chromatography (HPLC-UV) Method.  High pressure liquid 
chromatography-ultraviolet spectroscopy (HPLC-UV) was performed on an Agilent 1100 series 
HPLC (LC1027) equipped with a binary pump, DAD detector, auto sampler and a YMC pack Pro 
C18 4.6 x 50 mm ID, 12 nm pore size, 5 μm particle size column AS12S05-0546WT No. 
040510798(W).  Elution was achieved by a gradient method  from 10 to 95 % of solvent B (98% 
acetonitrile, 2% water, 0.1% triflouroacetic acid) in solvent A (98% water, 2% acetonitrile, 0.1% 
triflouroacetic acid) at 0.5 mL/min for 15 min.  Column and samples were maintained at 25 ⁰C.  
NAP and VAN concentrations were determined using 275 nm and 230 nm wavelengths, 
respectively.  
Thermal Analysis Methods 
Differential scanning calorimetry (DSC).   DSC analysis was conducted in hermetically 
sealed DSC pans on a TA Instruments Q100 calorimeter (New Castle, DE).  The samples were 
equilibrated at 25 ˚C then heated at 10˚C/min to 275 ˚C.  All DSC samples were weighed at 3.1 
mg ± 0.2 mg.   
DSC Heating/Cooling Cycling Experiments.  The 0.11 MF and 0.80 MF NAP:VAN 
mixtures were heated and cooled in hermetically sealed DSC pans and analyzed by DSC.  The 
mixtures were weighed (3.1 – 3.2 mg) directly into tared DSC pans.  The samples were equilibrated 
at 25 ˚C then cycled between 150 °C and 10 °C at 10 °C/min two times.  
Thermal gravimetric analysis (TGA) was performed on a Q500 analyzer at 10 °C/min 
from 25 °C to 275 °C in a platinum pan under dry nitrogen at 90 mL/min.   
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Results and Discussion  
Naproxen Vanillin Organic Solubility Experiment 
The solubilities of NAP and VAN in several organic solvents were determined by HPLC-
UV (Table 2).  Both compounds were soluble in all of the solvents screened except toluene and n-
heptane.  The organic solubility of VAN was lower in the solvents tested than NAP.   The 
precipitates of the organic solubility screen were analyzed by XRPD and DSC and did not show 
any new forms in EtOAc, EtOH, and MeOH (Figure 1).  Also, the DSC analysis of the original 
compounds matched the precipitates from the organic solubility screen, and no new forms or 
degradation was detected (Figure 2).  The other solvents (toluene and n-heptane) were not analyzed 
by XRPD due to an insufficient amount of precipitate recovered after evaporation.   The data 
supports future solvent evaporation experiments between NAP and VAN because of the neutrality 
of the compounds in the organic solvents and the mutual solubility in the solvents. 
Phase Diagram 
The presence of a eutectic was investigated in the mixtures prepared for the phase diagram 
of NAP and VAN.  Before DSC analysis, the physical mixtures were analyzed by XRPD and 
showed that crystalline VAN and crystalline NAP were detectable in all of the NAP:VAN solid 
mixtures, confirming immiscibility in the solid state (Figure 3) [23 – 38]. The melting temperatures 
of NAP and VAN were determined by DSC analysis and then compared to the other mixtures 
(Figure 4).   
 The NAP:VAN mixtures prepared for the phase diagram shows the formation of a eutectic 
mixture at 0.11 MF and melt at 75.2 ˚C.   The vertical line moving down the figure begins at the 
onset melt of VAN (top trace, Figure 4), and then follows the melt depression of VAN due to the 
presence of NAP in the mixtures to the 0.11 NAP:VAN mixture.  The eutectic melt is measured 
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   Slurry Concentration (mg/mL) 
Actual Concentration 
(mg/mL) 
Organic 
Solvent 
Naproxen 
(mg) 
Vanillin 
(mg) Naproxen Vanillin Naproxen Vanillin 
NMP 1.7 3.1 6.8 12.4 > 7 4.2 
DMSO 1.8 1.8 7.2 7.2 > 7 2.6 
EtOH 2.1 2.1 8.4 8.4 > 8 2.6 
MeCN 2.1 2.3 8.4 9.2 > 8 4.2 
EtOAc 1.4 2.4 5.6 9.6 > 5 2.8 
MeOH 2.1 2.8 8.4 11.2 > 8 3.7 
Toluene 1.2 2.1 4.8 8.4 n/a n/a 
n-Heptane 1.5 1.4 6 5.6 n/a n/a 
 
Table 2.  Organic solubility of NAP and VAN as determined by HPLC-UV.  The solubilities of 
NAP and VAN in toluene and heptane were undetermined. 
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Figure 1.  The PXRD diffraction patterns of NAP (top) and VAN (fourth trace from bottom) were 
compared to precipitates from the organic solvent screen as labeled in the figure.  No new forms 
were detected. 
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Figure 2.  The precipitates of NAP and VAN from the slurries in organic solvents are compared 
to the onset melt of the original compounds NAP (bottom trace) and VAN (top trace).  The 
precipitates of VAN in EtOH (second from top) and MeOH (third from top) do not show 
degradation (exothermic rise) until after the melt.  The precipitates of NAP in MeOH (third from 
bottom) and EtOAc (second from bottom) also do not show degradation until after the melt. 
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Figure 3.  XRPD overlay of ball milled samples of NAP and VAN prepared for the phase diagram.  
The mixtures are organized with VAN at the top of the figure and then increasing NAP in the 
mixtures moving down the figure.  No other forms besides NAP and VAN were detected. 
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Figure 4.  Thermogram of DSC overlay of NAP VAN physical mixtures as analyzed in 
hermetically sealed DSC pans at 10 °C/min.  The eutectic mixture is at 0.11 MF and melts at 75.2 
˚C (third trace from top). 
  
104 
 
 
 
by the onset melt, and the liquidus melt is measured by the maximum peak temperature of the 
resulting melting endotherm as many studies have previously performed by most researchers [25 
– 27].   One endothermic melt occurs between the 0.1 – 0.4 MF NAP:VAN mixtures, which reflect 
a solid solution is formed between NAP and VAN [20, 23].  After the initial melt of these mixtures, 
the resulting melting endotherm returns to baseline at slightly higher temperatures.   
 The resulting maximum temperature of the endotherm correlates to the melting of NAP in 
the mixture.  The difference between the peak maximum temperature in the resulting melting 
endotherm between the 0.1 and 0.2 MF mixture are slight.  At the 0.25 MF NAP:VAN mixture, 
the maximum peak temperature of the endotherm is more noticeable at around 100 ˚C (fifth DSC 
trace from top, Figure 4).  When the drug content was decreased in the mixtures, the resulting 
melting endotherm gradually shifted to a lower temperature and the resulting melting endotherm 
broadened, losing its sharp, distinct appearance.  As the NAP:VAN ratio further decreased, as in 
the 0.1 – 0.4 NAP:VAN mixtures, the DSC curves showed only one endothermic peak, 
corresponding to the melting of VAN.  The melting temperatures of the 0.5 – 0.9 MF NAP:VAN 
mixtures correspond to an initial eutectic melt, followed by a broadening of the resulting melting 
endotherm due to excess temperature of the NAP melting at higher temperatures until the onset 
melt of pure NAP (bottom trace, Figure 4).   
The NAP:VAN mixtures display the melting behavior of a monotectic system.  A 
monotectic system contains mixtures where the lower melting compound is only slightly affected 
by the presence of the higher melting poorly soluble API is present [2].  This causes a lowering in 
the melt depression of the API as the amounts of the lower melting compound is increased and the 
corresponding amounts of API is decreased in the mixtures.  This phenomenon can be seen in the 
105 
 
 
 
phase diagram in Figure 5.  The ability of VAN to depress the melt of NAP is due to the solubility 
and miscibility of NAP and VAN.  
 The resulting melting endotherm of NAP is not detected by DSC analysis in mixtures that 
contain less than 11% NAP.  Only the VAN melt is detected, which is significant because a solid 
solution may be formed.  The melt of NAP is most depressed at the eutectic mixture of 0.11 MF.  
As the amounts of NAP is increased above the eutectic mixture, the solubility and miscibility of 
the two compounds is exceeded, at the melt of NAP shifts back to its original melting temperature.  
At this point, the endotherm of NAP is depressed less as more NAP is added to the mixture, and 
the vertical line in the figure reflects the maximum  
 The NAP:VAN system  contains a eutectic melt at 0.11 MF NAP:VAN and the eutectic 
temperature, by DSC analysis, is 75.2 ˚C (E, Figure 5).  There are two mixed phases on the left 
and right of the eutectic mixture, above the solidus line and under the liquidus line.  The mixed 
phases are mirror images of VAN and NAP and are separated by the eutectic point E on the figure.  
Also, after the eutectic mixture, the lowest melting endotherm changes only slightly to a depressed 
temperature (~ 0.2 ˚C) as the amount of NAP increases in the mixtures.  The rising liquidus curve 
corresponds to the drug solubility in the liquid VAN. 
The purpose of the DSC/TGA analysis of the NAP:VAN mixtures is to determine if VAN 
is melting and degrading at the melting temperatures of NAP (Figure 6).  The 0.10 MF NAP:VAN 
mixture was analyzed and the resulting melting depression of VAN occurs at 3 °C (76 ˚C) below 
the original onset melt of VAN (81 °C).  The melt of NAP in the 0.10 physical mixture is not 
indicated due to the solubility of the compound in VAN at 70 ˚C.  The DSC/TGA data also 
indicates simultaneous melting and weight loss of both compounds when heated after the initial 
melt of VAN.  The 0.10 MF NAP:VAN mixture has an exothermic event at 200 ºC that may 
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Figure 5.  Phase diagram of NAP:VAN mixtures that shows the depression of vanillin from the 
onset melt of VAN to the eutectic mixture (E) at 0.11 MF at the eutectic temperature at 75.2 ˚C 
(Te).  When more NAP is added to the mixture after E, the liquidus curve reflects the solubility 
of NAP in VAN at higher temperatures.  When more VAN is added to mixture, on the left side 
of E, the melt of VAN is depressed as more NAP is added to the mixtures. 
 
  
107 
 
 
 
correlate to a solid-solid transition due to the presence of a new form or degradation.  A DSC 
heating/cooling experiment was designed to see if the mixtures were able to reform after melting 
and weight loss.   
 DSC Heating/Cooling Experiment 
 The physical mixtures prepared for the phase diagram demonstrated the melting behavior 
of NAP and VAN as soluble and miscible in proportions that contain less NAP below the eutectic 
mixtures (11% NAP/ 89% VAN) in the liquid state by DSC analysis.   This is apparent because as 
the % of NAP increases above 11% mixtures prepared for the phase diagram, the NAP endotherm 
increases in the onset melting temperature and the resulting melting endotherm separates from the 
VAN resulting melting endotherm.  XRPD analysis of the mixtures also confirmed that NAP and 
VAN are not soluble and immiscible in the solid state.  To further determine if the NAP:VAN 
mixtures would be able to reform to the original compounds after melting, a DSC heating/cooling 
experiment was designed. 
 The 0.11 MF eutectic mixture (Figure 7) and the 0.8 MF NAP:VAN mixture (Figure 8) 
were heated and cooled to determine if the mixtures were able to reform to the original compounds 
after melting.  The eutectic mixture melted at very similar temperatures during each heating cycle 
(75.2 ± 2 ˚C) but did not reform until the heating stage after the initial melt and cooling of the 
mixture.  Two solid-solid state transitions (at 28.6 °C and 45.3 ˚C) indicate that recrystallizations 
or polymorphism may be occurring during this heating step.  This was also shown in Chapter 2 of 
this work, where the DSC heating/cycling experiment on the 0.442 MF U:BA eutectic mixture 
reformed to the original compounds during the cooling process after the initial melt.  The thermal 
behavior of the 0.8 MF NAP:VAN mixture was similar to the 0.11 MF NAP:VAN mixture, and 
also reformed during the heating cycle after the initial melt and cooling processes.  The 0.8 MF 
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Figure 6.  The DSC/TGA overlay of 0.10 MF physical mixture (DSC/TGA top traces) was 
compared to the DSC traces of NAP (middle trace) and VAN (bottom trace).  All DSC samples 
were analyzed in hermetically sealed pans. 
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mixture melted between 76 – 77 ˚C and reformed during heating in multiple exothermic events 
from 41 – 56 ˚C.  These events may be multiple solid – solid state transitions.  However, the 
NAP:VAN mixtures consistently reformed to the original compounds after at least two cycles of 
heating and cooling. 
 0.11 MF Eutectic Mixture Solid State Characterization 
The 0.11 MF NAP:VAN eutectic mixture was prepared by the fusion method and analyzed 
by DSC, XRPD, and HPLC-UV to determine degradation.  The eutectic mixture was also 
compared to the 0.11 MF NAP:VAN physical mixture, with the main difference between the 
samples is that the physical mixture was ball milled and not melted before analysis.  The DSC 
analysis of the 0.11 MF NAP:VAN physical mixture and the 0.11 MF NAP:VAN eutectic mixture 
are very similar (Figure 9).  Both mixtures contain a slight melt depression of VAN (6 ˚C) and the 
melt of NAP is not detected.  The DSC trace rises slightly from baseline after 150 ̊ C that is present 
in both mixtures and is most likely due to the compounds degrading after melting.  The 0.11 MF 
NAP:VAN physical mixture and the eutectic mixture both melt and degrade identically.  The 
eutectic mixture contained less crystallinity after melting when compared to the physical mixture. 
However, the XRPD diffraction patterns of the eutectic mixture and the physical mixture did not 
show any new forms or an increase in amorphous content.  VAN (top trace) and NAP (bottom 
trace) are present during all of the successive melts of the 0.11 MF NAP:VAN mixture (traces 
second – fourth from top, Figure 10).   
 The XRPD data of the 0.11 MF NAP:VAN physical mixture was compared to the 0.11 MF 
NAP:VAN eutectic mixture formed after melted and cooled three times and the 0.8 MF mixture 
melted and cooled once.  These samples were also compared to the original compounds (NAP, 
VAN top and bottom DSC trace, Figure 10).  None of the mixtures, despite melting and cooling 
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Figure 7.  The 0.11 MF eutectic mixture does not degrade when heated between 10 – 150 ˚C.  The 
mixture melts and the resulting endotherm at 76 - 78 ˚C is reproducible.  The original components 
reform in two exothermic events at 28 and 45 ˚C.  
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Figure 8.  When the 0.8 MF NAP:VAN mixture is heated to 150 ˚C then cooled to 10 ˚C, the melt 
is reproducible and does not show degradation.  After melting, the original compounds are 
reformed when heated from 40 – 55 ˚C. 
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in succession, did not produce any new forms or degradation.  The 0.8 MF NAP:VAN mixture 
also contained NAP and VAN, but the peaks from the NAP diffractogram pattern were much more 
prevalent in this mixture, as would be expected in mixtures that contained increasing amounts of 
NAP and decreasing amounts of VAN (trace second from bottom, Figure 11).  No degradation 
was present in this mixture as well.   
 The 0.8 MF NAP:VAN mixture, after melting and cooling, is a physical mixture that 
contains NAP and VAN.  The 0.8 MF NAP:VAN mixture was also analyzed by DSC and TGA 
before (red, bottom DSC/TGA trace) and after melting (blue, top DSC/TGA trace, Figure 11).  The 
0.8 NAP:VAN physical mixture (red trace, bottom) and the 0.8 MF NAP:VAN melted mixture 
(blue trace, top) show similar melting behaviors which would be consistent with a reversible 
melting reaction.  One difference between the two samples would be the melted mixture has a 
depressed melt around 5 ˚C below the melt of the physical mixture.  Also, the resulting weight loss 
of the melted mixture is decreased by 5% as well.  Overall, it seems that the melting behavior of 
the NAP:VAN mixtures are similar regardless of the amount of NAP or VAN present in the 
mixtures and before and after melting. 
Solid dispersions, prepared by the fusion method, showed the same thermal behavior as 
the physical mixtures of the same compositions at similar temperatures.  The similarities between 
the DSC data for the 0.11 MF NAP:VAN  solid dispersions, even when melted multiple times, 
and the corresponding physical mixtures (Figure 12) are similar and indicate the absence of a well-
defined chemical interaction between NAP and VAN.  There is a noticeable pattern in the 
depression of the endotherm that is depressed from the melt of the physical mixture (Figure 12, 
trace second from top) and the melt of the mixture after the solid dispersion was formed by 
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Figure 9.  The DSC and TGA of the 0.11 MF physical mixture (top) and the eutectic mixture 
(below) are compared.   
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Figure 10.  XRPD overlay of 0.11 MF physical mixture (Pre-Melt) compared to the mixture 
melted once (Melt 1x), twice (Melt 2x), three times (Melt 3x), and the original compounds VAN 
(top trace) and NAP (bottom trace).  The 0.8 MF mixture also (second from bottom), after melted 
once and cooled, does not have any form changes. 
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heating and cooling in three cycles (Melt 3x, DSC trace second from bottom.)  The resulting 
melting endotherm of the physical mixture has an onset eutectic melt at 75.8 ˚C (second trace from 
top, Figure 12).  The onset melt of the 0.11 MF NAP:VAN solid dispersion, that was melted and 
cooled three times, is 72.9 ˚C (second to bottom trace, Figure 12).  The significance of the change 
in temperature of almost 3 ˚C may be that the eutectic mixture is the solubility of NAP in VAN is 
thermodynamically favored, but such a small difference melt depression temperature would likely 
have no effect on solubility or dissolution rate. 
 The solid dispersion of the 0.11 MF NAP:VAN eutectic mixture was analyzed by PLM 
HPLC-UV (Figures 13 and 14).  The PLM shows crystallinity resulting from the formation of a 
solid dispersion at 68 ˚C.  This temperature was determined visually (sample was completely 
melted) and the temperature was indicated by the digital thermometer on the IKA heated stirrer.  
This mixture melts at 7 °C below the measured 75.2 ˚C eutectic temperature by DSC analysis of 
the physical mixture (Figure 5).  PLM shows the three phases of the solid dispersion at 68 ˚C 
 (Figure 13):  the liquid phase (circle at bottom), the mixed phase (bottom right corner), and the 
solid phase (white mass middle and top).  After 24 hours, the solid dispersion is completely cooled 
and is a hardened to a crystalline solid dispersion (Figure 14).  The white mass consists of VAN 
crystals and the blue particles is NAP.  NAP may be inserted into the crystal lattice of VAN 
interstitially or by substitution.   
HPLC-UV analysis was utilized to detect changes in the chemical composition of the 0.11 
MF eutectic mixture and the 0.8 MF mixture.  The mixtures were prepared as solid dispersions by 
melting and cooling.  A weighed portion of the 0.8 MF mixture solid dispersion (melted and cooled 
in once cycle) was analyzed in triplicate and no degradation was detected.  The solubility of NAP 
analyzed by HPLC-UV in the experiment was also less than expected in the mixture (Table 3).   
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Figure 11.  The 0.8 MF mixture was analyzed was by DSC and TGA before and after melting.  
The DSC and TGA show similar melting behavior and weight loss and no degradation occurring.  
  
117 
 
 
 
 
 
 
 
 
 
Figure 12.  The 0.11 MF NAP:VAN physical mixture (second trace from top) was analyzed by 
DSC and compared after melting once (third trace from top), melting twice (third from bottom), 
melting three times (blue, second from bottom), and the original compounds (VAN at top, NAP at 
bottom.)  The onset melts of the mixtures are depressed slightly after each melting cycle and no 
degradation is detected. 
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This discrepancy may be due to the majority of NAP was not dispersed homogeneously in the 
portion of the 0.8 MF solid dispersion dissolved for analysis.  Insufficient mixing may also be an 
issue because the viscosity of VAN is greater than NAP even at small percentages present in the 
mixtures.  The 0.11 MF mixture was also analyzed by HPLC-UV analysis (Figure 17), and four 
samples were compared:  the physical mixture (P1), the solid dispersion prepared by one 
melting/cooling cycle (E1), the solid dispersion prepared by two cycles (E2), and then a final 
sample prepared in three cycles (E3).    The retention times of the peaks of the standards of NAP 
(N) and VAN (V) were compared to the samples to detect changes in retention times of the, the 
areas under the curve (AUC), and if new degradant peaks were present (Figure 17).  The peaks of 
the standards matched all of the sample peaks in the mixture and did not show evidence of 
degradation.  Also, the peaks of the samples do not show a shift in retention times and there was 
no presence of new degradant peaks.  These findings were also consistent in the 0.8 MF mixture 
that was prepared in one heating/cooling cycle.  The full recovery of NAP in the 0.8 MF 
NAP:VAN mixture signifies that all of the NAP:VAN melts in the phase diagram are reversible 
and not limited to the 0.11 MF NAP:VAN eutectic mixture. 
 Solubility experiment of NAP and 0.11 MF mixture in DI Water and PBS 
The solubility of NAP was compared to the solid dispersions of the 0.11 MF NAP:VAN eutectic 
mixture in DI Water and PBS at room temperature and 37 ˚C conditions.  The GSE, as mentioned 
previously, estimated the aqueous molar solubility of the compound at room temperature.  
Therefore, the solubility of NAP at room temperature and at 37 ˚C was measured.  The solubility 
in PBS was determined because PBS is often used for formulations that may be dosed 
intravenously.  The condition of 37 ˚C was also chosen for DI Water and PBS, because of the 
association between intrinsic dissolution testing and correlated human in vivo testing.   Therefore,  
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Figure 13. The 0.11 MF NAP:VAN mixture was analyzed by microscopy immediately after 
melting into a clear solid solution.  The photomicrograph contains white VAN crystals and NAP 
blue crystals that form a crystalline solid dispersion.  There is also some liquid present (circle at 
bottom) and a mixed phase of solid and liquid (bottom right hand corner).  The middle white line 
is 20 μm for scale. 
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Figure 14.  The 0.11 MF NAP:VAN mixture was analyzed 24 hours after sampled at the 68 ˚C 
eutectic temperature.  The sample is completely cooled is a crystalline solid dispersion of NAP 
and VAN.  The middle white line in the figure is 20 μm for scale. 
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Figure 15 and Table 3.  The 0.8 MF NAP:VAN  mixture (melted and cooled in one cycle) was 
solubilized in DMSO and analyzed in triplicate (Samples A, B, and C in Table 3) by HPLC-UV.   
The concentration of NAP and VAN in a small portion (1.3 mg) of the solid dispersion).  No 
degradation was detected. 
  
Sample Name Inj Vol (μl) Peak Name RT (min) Area (μV*sec) Dilution
Conc 
(mg/mL)
Target Con 
(mg/mL)
% Target 
Conc
80 NAP:VAN Melt 1x A 5 VAN 7.976 210754 1 0.0069 0.009 76.66
80 NAP:VAN Melt 1x A 5 NAP 13.811 378500 1 0.0548 0.0559 98.03
80 NAP:VAN Melt 1x B 5 VAN 7.974 210059 1 0.0068 0.009 75.55
80 NAP:VAN Melt 1x B 5 NAP 13.813 382558 1 0.0554 0.0559 99.1
80 NAP:VAN Melt 1x C 5 VAN 7.97 379034 1 0.0068 0.009 75.55
80 NAP:VAN Melt 1x C 5 NAP 13.814 207449 1 0.0549 0.0559 98.21
VAN Conc Average 0.0068
Standard Deviation 5.77E-05
NAP Conc Average 0.0550
Standard Deviation 0.0003
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Figure 16.  The HPLC-UV analysis of the 0.11 MF eutectic mixtures analyzed in triplicate (E1 – 
3) contain NAP (ret time 7.56 min) and VAN (ret time 4.81 min).  The NAP standard peaks are at 
7.56 retention time (N, bottom).  The 0.11 MF physical mixture (pre-melt) contain peaks that 
match the retention times of VAN and NAP (P1 – 3).  The eutectic mixture does not contain any 
peaks that do not match VAN or NAP (E1 -3) and does not contain any degradation after melting.   
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PBS may be chosen for further dissolution testing, if necessary.  The measured NAP solubility in 
DI Water at room temperature was 0.05 mg/mL at pH 4.4 (Table 4).  The solubility of NAP 
increases slightly to 0.07 mg/mL when slurried at 37 ˚C in DI Water, but the pH remained at 4.4.  
The measured NAP solubility in PBS at room temperature was measured at 0.9 mg/mL at pH 6.0, 
but increased slightly to 1.3 mg/mL at pH 5.88 when heated to 37 ˚C.  The solubility of NAP 
increased slightly with increased temperatures above ambient conditions.  The solubility of NAP 
was higher in buffered conditions near pH 6, as would be expected of a compound with a pKa of 
4.2.  Higher aqueous solubility is usually correlated with values above the pKa when more of the 
compound is ionized.   The XRPD analysis of the filtrate of NAP for all conditions and 
concentrations confirm that NAP did not change form during the experiment.  Therefore, when 
the eutectic mixture of NAP and VAN was tested for solubility, the benchmarks for NAP has been 
established. 
 The 0.11 MF eutectic mixture was prepared at two NAP concentrations at 0.5 mg/mL and 
2.3 mg/mL to ensure that the slurries were saturated by NAP in DI Water and PBS, respectively.  
The eutectic mixtures in both conditions did not have higher solubility than NAP alone.  The 
solubility of NAP was slightly lower in the eutectic mixture in DI Water in both conditions and in 
PBS at 37 ˚C.  The solubility of NAP and the eutectic mixture was highest in PBS at 37 ˚C.   
However, the solubility of NAP at 37 ˚C was slightly higher (1.3 mg/mL) than the eutectic mixture 
(1.14 mg/mL) in the same conditions.   
 The particle size of NAP was recorded, by PLM, after 48 hours of slurry in both media, 
and was measured between 1 – 5 μm.  This particle size was compared to the slurries of the eutectic 
mixture in both conditions and between the solid dispersion and the native drug.  However, the 
solubility of NAP and the eutectic mixture was measured to be highest in PBS at 37 ºC than DI  
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Table 4.  NAP solubility was measured in DI Water and PBS at room temperature and at 37 ˚C.  
The solubility of NAP increased with higher temperatures  and at pH values (column far right) 
above the pKa at 4.2.  This is reflected in the % recovery (third column from right) that lists the 
% of NAP dissolved in the media at the conditions listed.   
 
 
  
Naproxen Solubility
Average 
Conc 
Naproxen 
(mg/mL)
St Dev 
% 
Recovery 
(Avg)
Max Conc 
(mg/mL) pH final
DI Water at RT 0.05 4.16E-04 6.84 0.5 4.47
DI Water at 37 ˚C 0.068 4.36E-04 14.98 1 4.78
PBS at RT 0.93 2.36E-02 57.89 2 5.88
PBS at 37 ˚C 1.3 7.67E-02 64.21 2 6.2
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0.11 MF Eutectic 
Mixture of  
NAP VAN 
Ave 
Conc 
NAP 
(mg/mL) 
St Dev  
% 
Recovery 
(Avg) 
NAP 
(Solubility 
mg ) 
Average 
Conc 
VAN 
(mg/mL) 
St 
Dev 
(±) 
% 
Recovery 
(Avg) 
VAN 
Solubility 
(mg) 
Solubility 
MF 
(Recovered) 
pH 
final 
DI Water (RT) 0.035 0.001 6.30 0.525 2.550 0.018 88.25 38.250 0.090 4.37 
DI Water (37 ˚C) 0.061 0.004 11.00 0.060 2.648 0.134 84.98 39.750 0.100 4.22 
PBS  (RT) 0.94 0.01 41.59 14.1 8.815 0.093 73.460 132.225 0.066 5.8 
PBS (37 ˚C) 1.135 0.041 49.36 17.025 10.797 0.095 89.98 161.95 0.065 5.51 
 
Table 5.  Solubility of the 0.11 MF NAP:VAN  eutectic mixture in DI water and PBS at 37 ˚C 
and at ambient temperatures was determined by HPLC-UV analysis.  The solubility of NAP in the 
eutectic mixture was similar as NAP in that increasing temperature and higher pH produced higher 
solubility.  The NAP and VAN solubility could be calculated to determine the mole fraction that 
was solubilized in the media.  The PBS mixture, although higher in overall solubility of NAP and 
VAN, had less amounts of NAP and VAN (~ 0.065 MF NAP in sample) dissolve in solution than 
the original 0.11 MF NAP:VAN mixture. 
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Water, most likely due to the higher pH  (~ pH 6) and temperature.  However, the 0.11 MF 
NAP:VAN mixture did not show an increase in solubility over NAP alone.  This may be due to 
some of the crystalline VAN did not release the drug into the aqueous slurry due to the solubility 
of VAN was also exceeded.  If the VAN crystal lattice does not dissolve, then the drug will remain 
in the solid and never be released. 
 
Conclusions 
The purpose of investigating a eutectic mixture in NAP and VAN is due to the significance 
of the role of solubility to the melting point and the partition coefficient as described by the General 
Solubility Equation (GSE) (Equation 1): 
Log Sw = -0.01 (mp -25) – log Kow + 0.5  Equation 1. 
The GSE can be utilized to predict the log of the aqueous molar solubility (log Sw), which is the 
amount of moles dissolved in 1 L of DI Water, of a non-electrolyte organic compound by the 
melting temperature (mp ̊ C) and the partition coefficient  (Kow ).  It is apparent by the relationships 
in Equation 1, that the melting point does not have as much of an impact on the molar solubility 
as the partition coefficient.  However, the melting temperature of NAP can be depressed by VAN, 
as shown in the phase diagram (Figure 5).  The eutectic mixture was successfully found at 0.11 
MF (11% NAP/ 89% VAN) and visually observed to melt at 68 ˚C.  Therefore, by utilizing the 
GSE with the eutectic melt, the new calculated aqueous solubility is expected to be near 0.30 
mg/mL, which is a 6x higher from the original experimental aqueous solubility of 0.05 mg/mL 
(Table 6).  When the eutectic mixture was tested at ambient and at 37 ˚C, the resulting solubility 
did not show such an increase in solubility.  This discrepancy might be due to the nature of the  
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Table 6.  The GSE for NAP with eutectic melt of the 0.11 MF mixture at 75˚C.  The new 
calculated aqueous solubility of NAP is 4.9x higher than the original solubility of NAP.  
 
  
MW 
(g/mol)
(mp ˚C) log Kow
Calculated 
Log  Sw
Calculated 
Aqueous 
Solubility 
(mg/mL)
melt 
depression (˚C)
New 
Calculated 
Log Sw
New Calculated 
Aqueous 
Solubility 
(mg/mL)
Change in 
Solubility
Naproxen 230.3 154 2.88 -3.67 0.05 -79 -2.99 0.30 4.9x
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crystal dispersion, which may decrease the dissolution rate by retaining the drug in the crystal 
lattice for a longer interval than the drug alone. 
 The solid dispersions of NAP and VAN were found not to be effective in improving NAP 
solubility in DI Water and PBS due partly because, unlike solid dispersions of NAP prepared using 
polyvinyl pyrrolidone (PVP) and cyclodextrins, dispersed systems prepared using VAN did not 
appear to contain any amorphous drug [6].  An amorphous drug is usually advantageous in 
dissolution by increasing the dissolution rate when compared to the crystalline form [2, 4, 5, 9].  
However, a possible disadvantage of the amorphous form is a loss of stability over me.  Therefore, 
although the NAP:VAN mixtures do not have higher solubility than NAP alone, the solid 
dispersion may increase the stability of the drug over time.   
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Chapter 6.  Conclusions and Future Considerations 
 Eutectic mixtures have been utilized in the world of metallurgy and industrial settings for 
a long while, and the possibility of being able to use eutectic mixtures with the same utility in the 
pharmaceutical world remains unlikely.  The nature of organic compounds remain fragile and 
thermally sensitive when compared to the metals forged in blends of steel alloys.  Innovative 
technology developed to unravel the mystery of eutectic mixtures press on with computer models 
that present theoretical phase diagrams of organic systems.  However, the tactile instruments of 
utilizing the models, and translating the theoretical to the practical, is the final chasm that has yet 
to be successfully negotiated. 
 In this work, three different small molecules:  AMG 517, glipizide, and naproxen were all 
mixed with a second small molecule to determine the presence of a eutectic by constructing the 
binary phase diagrams.  The investigation into the AMG 517 mixtures were difficult for the same 
reason as the search for eutectic mixtures in glipizide:  the thermal degradation of the API or the 
second compound.  If the mixtures include a compound that melts and degrades before mixing 
between the two compounds is achieved, then it is very difficult to find the eutectic mixture 
successfully.  In the AMG 517 mixtures, although the API was thermally stable, the co-crystal 
formers were not and caused degradation to interfere with the identification of the eutectic mixture.  
However, the glipizide was thermally unstable at temperatures below the melting point, which 
presented an obstacle to determining the eutectic mixture in the system too difficult to overcome. 
 Finally, the eutectic mixture in the naproxen vanillin binary system was successfully 
identified at 0.11 MF (11% naproxen/ 89% vanillin).  The system formed a monotectic system 
where naproxen and vanillin were miscible and soluble in all compositions in the liquid phase and 
immiscible and insoluble in the solid phase.  Some reasons the eutectic mixture was successfully 
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identified were the mutual solubility and miscibility of the two compounds, the thermal stability 
of both compounds when melted and cooled, and the ability to mix the compounds successfully 
by melting.  The 0.11 MF mixture, however, did not show an advantage in solubility when 
compared to naproxen alone in DI Water and PBS.  The eutectic mixture formed a crystalline solid 
dispersion that does not always lead to higher solubility.  In some cases, the crystal lattice retains 
the API for a period of time that retards the release of the drug into the media.  However, an 
advantage of a crystalline solid dispersion may be an increase in stability.  This may explain the 
lower solubility of the eutectic mixture, where the solubility of vanillin was exceeded in both 
media.  Therefore, if the vanillin crystal lattice does not dissolve completely, naproxen may not be 
released into the aqueous media. 
 In conclusion, the search for eutectic mixtures is a worthwhile endeavor in which the 
current state of pharmaceutical development includes more and more API candidates that suffer 
from poor physicochemical characteristics.  Future work will continue to search for other 
candidates of eutectic mixtures, expand the organic solvents tested for the API’s tested for future 
mixing experiments, and test the eutectic mixture of naproxen and vanillin in intrinsic dissolution 
studies.  The search for technologies to expand the strategies to change the poor physicochemical 
characteristics of API candidates in development continues to evolve and, hopefully, present new 
opportunities that would have otherwise been unknown. 
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Chapter 7.  Appendix 
 
Compilation of data obtained by XRPD, DSC, TGA, particle size, polarized light microscopy 
(PLM), and near Infrared (NIR) analytical techniques. 
 
 
 
Urea Benzoic Acid Mixtures (U:BA) 
Heating/Cooling DSC Experiments 
0.2 MF U:BA heated and cooled three times.  
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0.6 MF U:BA Mixture  
Analyzed in DSC heating/cooling experiment cycled twice.  Run once. 
 
 
 
0.8 MF U:BA Mixture 
Analyzed in DSC heating/cooling experiment cycled three times.  Run once. 
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AMG 517 Anhydrous (AMG 517) in Solvent Screen 
 
 
Some interaction of AMG 517 and organic solvents.  MEK chosen because no interaction seen 
with AMG 517. 
 
 
 
Onset melt of AMG 517 in various organic solvents does not change significantly. 
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AMG 517:SA System 
 
 
 
 
 
 
 
 
XRPD diffractogram this an overlay of the powder patterns of AMG 517 /SA (SAC in the 
figure) and added amounts of SA and AMG 517.  The starting material is the middle trace 
(SAC) and added amounts of SA is the upper half of the diffractogram while added amounts of 
AMG 517 was used to prepare the bottom half of the figure.  No unknown forms was detected.  
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0.5 MF AMG 517 SA BM mixture did not form a co-crystal, which would be characterized by 
one endotherm with an onset melt of 159 °C and the AMG 517 endotherm at 222 – 228 °C.  
 
 
AMG 517 and CA did not form a co-crystal was slurried in MEK. 
 
189.91°C
168.01°C
136.9J/g
122.18°C
84.75°C
38.13J/g
-6
-4
-2
0
2
He
at
 F
lo
w 
(W
/g
)
0 50 100 150 200 250 300
Temperature (°C)
Sample: AMG 517 Sorbic Acid 0.50 MF 3
Size:  2.9100 mg
Method: 25-30@10C
Comment: AMG 517 Sorbic Acid 0.50 MF open pan 3
DSC
File: \\...\50MF AMG517 SORBIC ACID 3.002
Operator: CMorgan
Run Date: 12-Jan-2012 10:20
Instrument: DSC Q200 V24.8 Build 120
Exo Up Universal V4.7A TA Instruments
133.14°C
131.55°C
39.70J/g
115.97°C
112.94°C
18.34J/g
229.43°C
228.21°C
86.16J/g
134.12°C
132.84°C
136.8J/g
-12
-10
-8
-6
-4
-2
0
2
He
at
 F
low
 (W
/g
)
0 50 100 150 200 250
Temperature (°C)
                  1:1 AMG 517 Cin Acid in MEK–––––––
                  AMG 517 MEK–––––––
                  Cinnammic Acid MEK–––––––
Exo Up Universal V4.7A TA Instruments
138 
 
 
 
 
0.5 MF AMG 517:XYL in dioxane and water 
 
0.8 MF AMG 517 XYL in dioxane and water 
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Naproxen and Vanillin Mixtures 
 
The mixtures between 0.10 – 0.12 MF NAP:VAN were analyzed in duplicate to further refine 
the eutectic mixtureswere The melt of the 0.11 MF mixture included the lowest melt (74.8 ˚ avg) 
of the other mixtures.  All of the melts between 0.10 – 0.15 MF were very similar (± 0.5 ˚ C) and 
a slight rise at 150 ˚C in the baseline is most likely indicative of NAP melting and degrading. 
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The melts, as obtained by DSC analysis, of VAN (top), the eutectic mixture (second from 
top), the 0.11 MF physical mixture (second from bottom), and NAP is compared.   
 
 
0.5 MF NAP:VAN DSC/TGA Overlay 
 
DSC/TGA overlay of 0.5 MF NAP VAN mixture. 
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0.6 MF NAP:VAN DSC/TGA Overlay 
 
DSC hermetically sealed pans.   A sharp melt at 75.6 ˚C followed by degradation.  The TGA 
shows weight loss as expected for a mixture of 40% Vanillin/ 60% Naproxen.  The DSC/TGA 
overlay shows that vanillin has a slightly depressed melt followed by degradation.  The melt of 
naproxen is obscured by the previous degradation of vanillin.   
 
0.7 MF NAP VAN DSC/TGA Overlay 
 
TGA/DSC (herm) overlay of 0.7 MF NAP:VAN mixture.  Shows same behavior as 0.6 MF 
mixture. 
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0.9 MF NAP:VAN DSC/TGA 
 
Hermetically sealed DSC Pans.  VAN begins to melt and degrade upon heating from 50 ˚C 
onward.  Mixture is thermally sensitive and not viable for a phase diagram. 
 
 
Comparison of 0.8 MF NAP:VAN Physical Mixture and melted mixture. 
 
 
 
0.8 MF mixture melted once (second from bottom) then compared to the physical mixture  
(second from top) and compared to the original compounds VAN (top) and NAP (bot).  The 
physical mixture and the melted mixture match and do not contain any degradation or new 
forms. 
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NAP 48 hour slurry in PBS vs. DI Water at Room Temperature (RT) and 37 ˚C 
 
 
 
 
 
 
 
There was no form change by naproxen in PBS vs. DI Water at 37 ˚C at RT.  NAP (top trace) is 
compared to the isolated solids after a 48 hour slurry at 1mg/mL in DI Water at 37 ˚C (second 
trace from top), at 1 mg/mL in DI Water at RT (third trace from top), 2 mg/mL in PBS at 37 ˚C 
(second trace from bottom), and at 2 mg/mL in PBS at room temperature (bottom trace). 
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Naproxen Slurries in PBS and DI Water at RT and 37C 
 
 
 
PLM:  200x  48 hour slurry of NAP at 1 mg/mL at 37 ˚C.  The NAP particles are smaller than 5 
µm but has a tendency to conglomerate (20 – 50 µm in size). 
 
Naproxen Slurries in PBS and DI Water at RT and 37C (cont.) 
 
 
 
PLM:  200x of NAP slurry in DI Water for 48 hours at 1 mg/mL at RT. 
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PLM:  200x of NAP slurry in PBS for 48 hours at 2 mg/mL at 37 ˚C. 
 
 
 
 
 
 
 
Naproxen Slurries in PBS and DI Water at RT and 37C  
 
 
 
PLM:  200x of NAP slurry in PBS for 48 hours at 2 mg/mL at RT. 
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